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Kyphoscoliosis Peptidase (KY) is a skeletal muscle Z-disk protein that has been 
implicated in several inherited myopathies. The mechanism underpinning KY’s 
function has remained elusive, but previous research suggests that KY could have 
protease activity over generic substrates. However, protease activity over endogenous 
substrates have not been proven. The highly conserved transglutaminase/protease 
(TGN/PROT) domain is the only distinguishable feature within KY. This domain 
includes conservation of the three catalytic residues which have been shown to be 
required for enzymatic activity in cysteine proteases. Here, biochemical assays have 
shown that this domain is not enzymatically active. In addition, electroporations of the 
ky/ky mouse muscle with a KY version lacking the TGN/PROT domain indicates that 
this domain is not required for Z-disk localisation but is required for the rescue of 
atrophic muscle fibres.  
Here, in-silico analysis has shown that human KY (hKY) protein has gained a nuclear 
localisation signal (NLS) located upstream of the putative start site of the mouse and 
other vertebrate homologues. This NLS appears to be functional, as in contrast to the 
mouse KY protein, hKY shows nuclear localisation in C2C12 myoblasts and COS-7 
fibroblasts. Within electroporated adult mouse muscle hKY localises both to the Z-
disk and the nucleus. The Z-disc/nuclear localization of hKY is highly reminiscent of 
IGFN1, a known protein partner of mouse KY. Co-transfections of hKY and IGFN1 
in C2C12 myoblasts leads to strong accumulation of both protein in nuclear 
aggregates, while IGFN1 is not able to change localization of mouse KY to the 
nucleus. Thus, the mouse and human KY orthologues show different expression 
patterns. Further analysis shows that this NLS is conserved within primates and 
therefore may have evolved to facilitate the distinct biomechanics of primate muscles 
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1.1 Skeletal muscle structure 
1.1.1 Skeletal muscle structure 
Skeletal muscle is built up from bundles of muscle fibers, more commonly known as 
fascicles. Each fascicle is encased by the perimysium; connective tissue which 
provides support and integrity to the fascicle. Further stability and structural integrity 
are provided by another layer of connective tissue, known as the epimysium which 
encases the perimysium. Each muscle fiber is composed of bundles of myofibrils, 
muscle fibers are encased by the sarcolemma; a cell membrane which provides a 
scaffold to which myofibrils adhere (Figure 1.A). The basic units of myofibrils are 
sarcomeres whereby the normal organisation of sarcomeric proteins gives muscles 
their distinctive pattern. The sarcomeres are defined by their Z disks (Clark, et.al., 
2002), which form the boundaries of the sarcomere. The width of the Z-disk varies 
depending on fiber type, fast fibers having narrow Z-disks (~30-50nm), whilst slow 
fibers have wider Z-disks (~100nm). Z-disks are essential for contraction, the transfer 
of tension, and signalling (Luther, et.al., 2003). Thin actin filaments are tethered to the 
Z-disk via the positive end of their filament (barbed end). Thick myosin filaments are 
contained between these actin filaments which are extruding from the Z disk (Figure 
1.B) (Clark, et.al., 2002). Skeletal muscle is adhered to the bone via tendons, typically 
occurring at each end of the muscle. Tendons allow for the conversion of contractile 
forces into movement.  
The Z-disk is arguably the most important structure within the context of skeletal 
muscle, providing an anchor for proteins and a structural linkage along the muscle 
fiber (Luther, 2009). Thus, allowing for the transmission of tension and contractile 
forces along the fiber. The Z-disks are extremely strong structures, able to withstand 
large forces applied through them, throughout muscle contraction. Furthermore, an 
extremely large repertoire of proteins and their interacting partners localize to the Z-
disk, allowing many functions to occur including mechanosensing and signalling 
(Luther, 2009). Mutations within many of these proteins have a profound effect, 
causing a range of cardiac and skeletal muscle diseases (Frank and Frey, 2011). The 
identity of the mechanism regulating stretch sensors is still elusive, but it is widely 
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believed these sensory proteins are located at the Z-disk (Knöll, et.al., 2011). In order 
for a transcriptional response to occur these sensors would have to communicate with 
the nucleus, either through the action of signalling proteins, or through protein 
translocation to the nucleus. 
 
 
Figure 1. Schematic diagram of skeletal muscle structure. A) Muscle structure from 
bone attachment to myofibrils. Tendons are used to adhere muscles to bone. The muscle 
is encased by the epimysium. The muscle itself splits into different fascicles, which are 
encased by the perimysium. Each fascicle is built up of multiple muscle fibers which are 
encased by the sarcolemma. This image is available at 
https://open.oregonstate.education/aandp/chapter/10-2-skeletal-muscle/. Muscle fibers 
are formed through a multitude of myofibrils B) Sarcomere structure. Myofibrils are 
developed from horizontal and linear repeating sarcomeres. The Sarcomere is the basic 





1.1.2 Muscle Fibers. 
Muscle Fibers are divided into multiple fiber types, the proportion of these fibers varies 
significantly between individuals and species (Simonea and Bouchard, 1989; Klont, 
et.al., 1998). The muscle fiber type is determined by the differing isoforms of myosin 
heavy chain (MHC) that are expressed, alongside myosin light chain (MLC), and the 
myosin binding protein C (MBC), together these proteins form the thick myosin 
filament within the fiber. Originally muscle fibers were divided into two classes, type 
I (slow) and type II (fast). Type I fibers are oxidative, producing slow sustained 
contractions and are able to resist fatigue, these fibers are known for maintaining 
correct posture (Pocock, et.al., 2013, p.125-126). Conversely, type II fibers are divided 
into two distinct groups, type IIa fibers which are an intermediate being oxidative and 
glycolytic. Type IIb are glycolytic, producing powerful short contractions required for 
dynamic movement (Pocock, et.al., 2013, p.125-126). More recently, other 
intermediate fibers have been identified and can be characterised through myosin 
ATPase histochemical staining (Scott, et.al., 2001). Most skeletal muscles contain a 
mixture of both type I and type II fibers, although some muscles predominantly express 
one type. The soleus muscle is primarily composed of type I fibers, while the extensor 
digitorum longus muscle is primarily type II fibers.  
Muscle fibers are formed through the fusion of multiple myoblasts. Cell fusion occurs 
when two Z bodies (small complexes of alpha actinin and associated proteins) grow, 
fuse, and align to form the Z disk, allowing development of the muscle fiber (Sanger, 
et.al., 2006). This process requires dramatic remodelling of the cytoskeleton allowing 
formation of a large, interconnected network between sarcomeres (Wang, et.al., 2005). 
Muscle fibers are multinucleated and post-mitotic. It has been theorised that a single 
nucleus has a limited synthetic capacity and can only regulate the gene expression 
within a select region (Myonuclear domain (MND)) within the myofiber (Hall and 
Ralston, 1989; Pavlath, et.al., 1989). Although a single myonuclei is thought to control 
the gene expression within the MND, a uniformity of gene expression is seen across 
the muscle fiber, suggesting some cross talk between these regions. Conversely, it has 
been reported that different MND’s show differing levels of gene expression across 
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the muscle fiber (Wilkins, et.al., 2001). Myonuclei located at neuromuscular junctions 
and myotendinous junctions, express a specialized subset of genes relevant to these 
specialised regions of the muscle. This suggests that each MND is under the control 
of a single myonuclei, and expresses a subset of specialized genes needed for that 
region. A more recent study has suggested that not all myonuclei are positioned 
equally, and that there are multiple subsets of myonuclei, each having specialized rules 
that control myonuclei spacing (Perillo and Folker, 2018). This may explain the 
differences in gene expression which are observed along the myofiber.  
1.2 Skeletal muscle hypertrophy 
Muscular cells are postmitotic, they are long lived and require constant maintenance 
and upkeep. The active nature of muscle cells (myocytes) allows the generation of 
mechanical forces, which in turn produces a large variety of stressors, such as 
increased temperature, membrane lesions, and cellular tension (Morton, et.al., 2009). 
Skeletal muscle is extremely plastic and can go through vast changes, these changes 
are dependent on the external and internal stimuli muscles receive. Muscles adapt to 
the functional requirements put upon them, adapting through changes in muscle mass, 
fiber size, and the type of fibers expressed. 
Muscular hypertrophy is one form of adaptation, with prolonged resistance training 
muscle hypertrophy is prominent, leading to an increase in muscle size and thus 
strength. In untrained individuals muscle hypertrophy is nearly non-existent. Muscle 
hypertrophy increases muscle fiber size through the addition of contractile elements, 
such as actin and myosin, which leads to a larger cross-sectional area of the muscle 
fiber. Contractile hypertrophy occurs through the addition of new sarcomeres in series 
or in parallel with the fiber (Vierck, et.al., 2000). Further to this increase in fiber cross-
sectional area, expansion of the extracellular matrix (ECM) is observed which provides 
further support to these larger fibers (White, et.al., 2009). Conversely to this, muscle 





The protein derived growth factor ‘insulin-like growth factor 1’ (IGF-1) has been 
shown to induce hypertrophy in muscle fibers (Musarò, et.al., 1999), this occurs 
through the stimulation of the phosphatidylinositol-3 kinase (PI3K) / Akt pathway. 
Alongside inducing hypertrophy, IGF-1 can also block transcriptional upregulation of 
key mediators of muscle atrophy (protein degradative pathway). IGF-1 binds to the 
tyrosine receptor IGFR1 causing the phosphorylation of Insulin Receptor Substrate 1 
(IRS-1), which in turn activates PI3K (Rommel, et al., 2001). Subsequently PI3K 
activates Akt through phosphorylation. Akt has a large plethora of functions, this 
includes phosphorylation of tuberous sclerosis complex-1 and -2 (TSC1/2) proteins, 
leading to their inhibition. Inhibition of TSC1/2 releases the inhibition upon mTOR, 
 
Figure 2. The hypertrophic PI3K/Akt signalling pathway. A simplified schematic of the 
phosphatidylinositol-3 kinase (PI3K) / Akt pathway. Up-regulators of muscle hypertrophy 
are shown in green whilst down regulators are shown in red. Intermediates are shown in 
blue. The arrows signify protein activation, while the red lines with a horizontal line signify 
protein inhibition. The curved line represents the myonuclei membrane. This image has 




which has been shown to have an imperative role in integrating a variety of growth 
signals, such as nutritional stimulation and growth factors (Panzhinskiy, et.al., 2013).  
Activation of mTOR leads to protein synthesis, allowing growth of the fiber. Akt 
further aids the production of proteins utilising a distinct pathway, which is separate 
to the mTOR pathway. Akt inhibits GSK3, releasing the inhibition on the protein 
initiation factor eIF2B, allowing for an increase in protein synthesis, and aiding muscle 
hypertrophy. Furthermore, Akt activation leads to the inhibition of the Forkhead box 
transcription factors (FOXO) family. The FOXO family has a significant role in 
inducing atrophy (Sandri, et.al., 2004). This inhibition suggests, alongside inducing 
hypertrophy, that the PI3K/Akt pathway can significantly inhibit atrophy initiation.   
The initiation of exercise induced hypertrophy remains elusive, it is hypothesised that 
there are three main factors responsible for this initiation: mechanical tension, 
metabolic stress, and muscle damage (Schoenfeld, 2010). Mechanical tension is 
produced through force production and stretch. Both of these stimuli have a large effect 
on increasing muscle growth. To date, no definitive mechanosensory proteins have 
been identified, although a few candidates have been suggested such as Titin and 
FLNC (Wackerhage, et.al., 2018), both of which are Z-disk localizing proteins. 
Nucleocytoplasmic shuttling proteins such as Muscle LIM protein (MLP) which is 
encoded by Cystine and Glycine-rich protein 3 (Csrp3), have also been implicated as 
potential stretch sensors (Boateng, et.al., 2009; Vafidaki, et.al., 2015). A multitude of 
studies support metabolic stress as having a more important role in determining the 
hypertrophic response (Schoenfeld, 2013). The accumulation of metabolites such as 
lactate, initiates a stress induced mechanism which has been theorised to induce a 
hypertrophic response. Finally, muscular damage which can result from resistance 
training is thought to cause hypertrophy. This damage occurs in multiple forms; tears 
in the sarcolemma, basal lamina and supportive tissue are all seen. Alongside injury to 
contractile elements, and the cytoskeleton (Schoenfeld, 2010). This damage is believed 





1.3 Skeletal muscle atrophy 
Muscular atrophy is a loss of muscle mass through active protein degradation. Muscle 
atrophy is prevalent in a multitude of diseases, such as Chronic kidney failure and heart 
disease. The most prevalent form of muscle atrophy is seen within sarcopenia where 
muscle loss is observed through the process of ageing. Atrophy is also seen in response 
to certain stimuli, such as starvation or immobilisation of a limb, both of these can 
cause a varying range of muscular atrophy.  
Myostatin is a member of the transforming growth factor beta (TGFβ) superfamily. 
Overexpression of myostatin has been shown to induce muscle atrophy, myostatin null 
mice show vastly increased muscle mass (McPherron, et.al., 1997). Myostatin is 
therefore a key factor which promotes muscular atrophy. Myostatin has been shown 
to bind to the membrane bound activin type II receptor (ActRII), which in turn leads 
to the phosphorylation of Smad2/3 (Rebbapragada et.al., 2003). Also, phosphorylated 
Smad2/3 can form a heteromeric complex with Smad 4 which is able to translocate to 
the nucleus and inhibit gene transcription (Goodman and Hornberger, 2014).  
Furthermore, phosphorylated Smad2/3 can inhibit Akt activity, thereby preventing Akt 
induced hypertrophy and protein synthesis. The inhibition upon Akt releases inhibition 
upon the FOXO family. The FOXO transcription factors induce expression of MuRF1 
and MAFbx (Bodine et.al., 2001), genes involved within the upregulation of the 
ubiquitin-proteasome system. The ubiquitin-proteasome pathway is the primary 
pathway utilised within muscle atrophy, alongside other degradative pathways. 
Myostatin has also been shown to activate the Autophagy-lysosome system (Wang, 
et.al., 2015), another distinct protein degradation pathway utilised within muscle 
atrophy. Myostatin has also been linked to the inhibition of PI3, the upstream activator 






Muscular myopathies and a multitude of diseases are known to lead to a loss of skeletal 
muscle, within these cases pro-inflammatory cytokines are known to rise. TNF-α is a 
polypeptide cytokine which is linked to antitumor immune responses. TNF- α has been 
shown to trigger multiple cell responses and has been associated with muscular 
pathology (De Larichaudy, et.al., 2012). Importantly, TNF-α plays a significant role 
in promoting muscle atrophy. TNF-α binds to its receptor inducing the activation of 
IκB Kinase complex (IKK) through phosphorylation, this in turn leads to 
ubiquitination and degradation of IκB through the proteasome. IκB degradation leads 
to activation of NF-κB (Yaron et.al., 1998). Mice with constitutively active IκB have 
shown an upregulation of MuRF1, and when these mice are crossed into a MuRF1-/- 
background, there was a significant reduction in muscle atrophy. Thus, showing that 
 
Figure 3. The Myostatin atrophy signalling pathway. A simplified schematic of the 
atrophy promoting pathways. Upregulators of atrophy are shown in red, whilst 
downregulators of atrophy are shown in green. Intermediates are shown in blue. The 
arrows signify protein activation, while the red lines with a horizontal line signify protein 
inhibition. The curved line represents the myonuclei membrane. This image has been 




the removal of MuRF1 inhibits the atrophic ability of IκB signalling (Cai et.al., 2004).  
NF-κB also upregulates MAFbx through the p38 MAPK pathway (Ho, et.al., 2005; 
Zhang and Li, 2012).  
The Ubiquitin-proteasome system (UPS) plays an important role in muscle atrophy 
which has been thoroughly established (Bilodeau, et.al., 2016). Protein ubiquitination 
occurs throughout the body and is used as a signal for protein degradation. The 26S 
proteasome complex recognises ubiquitinated proteins and in an ATP dependent 
manner, leads to the proteolytic degradation of a variety of proteins. Ubiquitin chains 
are added to proteins via three enzymes: ubiquitin activating E1, ubiquitin conjugating 
E2, and ubiquitin ligase E3. Ubiquitin activating E1 binds with a ubiquitin molecule, 
passing the ubiquitin to ubiquitin conjugating E2. Ubiquitin conjugating E3 allows the 
linking of the Ubiquitin to a lysine residue of the target protein. The FOXO 
transcription factors promote expression of ubiquitin ligases. FOXO’s have also been 
shown to induce the autophagy/lysosome system (Bilodeau, et.al., 2016). 
Autophagic/lysosomal proteolysis has been shown to play a significant role in protein 
degradation within muscles. Inhibition of autophagic proteins leads to a dystrophic 
muscle through the build of protein aggregates and damaged organelles (Masiero and 
Sandri, 2010). Autophagy is a mechanism that takes cytoplasmic material and 
organelles and delivers them to a lysosome for degradation, damaged mitochondria 
and protein aggregates are cleared through autophagy. Multiple UPS genes are also 
able to upregulate genes involved within autophagy. Chaperone assisted selective 
autophagy (CASA) is a selective type of autophagy which is a tension induced 
degradative pathway essential for muscle maintenance, and protein turnover (Arndt, 
et.al., 2010). Instead of protecting and refolding damaged Z-disk proteins such as 
FLNC, these proteins are targeted for degradation while inducing the expression of 
new FLNC. CASA also facilitates the degradation of these damaged proteins. The 
chaperone associated ubiquitin ligase CHIP and p62 initiate CASA by ubiquitinating 
the target protein. BAG3 has been identified as being a key regulator of the CASA 
system, specifically coordinating the activity of the small heat shock proteins HspB8 
and HspB8 during the degradation of proteins post ubiquitination (Guilbert, et.al., 
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2018). Further to this, mutations within BAG3 cause a severe form of myofibrillar 
myopathy, characterised by protein aggregation, and muscle weakness. BAG3 has 
been shown to localise to the Z-disk, where it is imperative for FLNC turnover. BAG3 
also interacts with factors of the hippo system in order to induce FLNC transcription, 
thus aiding the replenishment of FLNC, further aiding Z-disk stabilisation (Jokl, et.al., 
2018). This mechanism suggests BAG3 is therefore a critical factor underpinning 
normal FLNC turnover in tension bearing cells and thus sarcomeric maintenance.  
1.4 Kyphoscoliosis peptidase 
1.4.1 The ky/ky Mouse 
Kyphoscoliosis peptidase (Ky) is imperative for normal muscular function. The first 
reported Ky deficiency (ky/ky) developed through a sporadic mutation within the BDL 
strain of mice. This ky/ky mouse showed the development of kyphoscoliosis which 
could be detected quickly post weaning (Dickinson and Meikle, 1973). The Ky 
mutation was identified through positional cloning, revealing a premature STOP codon 
caused by a CG deletion (Blanco, et.al., 2001). All ky/ky muscles are smaller and 
weaker than controls. This inherent muscular weakness likely contributes to the spinal 
abnormalities observed. Weakening of the paraspinal muscles contribute to this 
development, alongside preventing mice from reaching towards a ledge during the 
placing response test (Blanco, et.al., 2001) (Appendix). To date no phenotype has been 
observed throughout the embryonic development stage, highlighting the need for 
physical stressors and mechanical load to reveal muscular abnormalities, which are 
quickly observed post weaning.  
On average ky/ky mice have a body weight that is ~80% of the weight of the wildtype 
mouse.  During postnatal muscular growth, a cycle of fiber death and regeneration is 
extremely prevalent in the postural muscles, such as the soleus and paraspinal muscles. 
This is evident due to the vast number of internalised nuclei present within ky/ky fibers, 
which is a hallmark of fiber regeneration. Intriguingly, these muscles show an adaptive 
shift of the contractile protein isoforms, typical to that of type I slow muscles 
(Marechal, et.al., 1996). This adaption likely reflects an inability to cope with the 
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increased demand put upon muscles, associated with a higher body weight. At an 
ultrastructural level, the soleus presented with Z-disk thickening, A-line streaming, 
and overlapping of thick filaments (Beatham, et.al., 2004). The thickened Z-disk 
potentially reflects an inherent instability within the Z-disk, leading to an adaptive 
over-production of Z-disk proteins to aid stabilisation. Additionally, accumulation of 
sarcomeric proteins such as Filamin C (FLNC) and Xin aggregates are commonly seen 
within ky/ky myofibers, reflecting a reduced ability to degrade proteins. Furthermore, 
ky/ky muscles are unable to induce hypertrophy in response to mechanical overload 
(Blanco, et.al., 2001).  
The Z-disk co-chaperone BAG3 has been shown to be upregulated in Ky deficient mice 
and Zebrafish models (Jokl, et.al., 2018). As previously mentioned BAG3 is part of 
the CASA pathway, aiding the degradation and potential replenishment of FLNC. The 
authors also suggested that the BAG3 dysregulation seen could be the causative reason 
behind FLNC aggregation seen in ky/ky models. RNA profiling of the ky/ky mouse has 
shown an upregulation of stretch response proteins Ankyrin repeat domain 2 (Ankrd2) 
and Cystine rich protein 3 (Csrp3). Further to this, an upregulation of the energy 
transducing proteins Uncoupling protein 1 and 2 (Ucp1/2) is observed (Blanco, et.al., 
2004). The upregulation of BAG3 seems to be a significant hallmark of the ky/ky 
phenotype, likely contributing to the large protein aggregates seen within these 
models. Again, the upregulation of the stretch receptors Ankrd2 and Csrp3 show an 
inability of the muscles to respond to mechanical overload, highlighting Ky’s critical 
function in adapting and responding to mechanical stresses. 
1.4.2 The Ky Gene  
The mouse Ky gene encodes a 72 kDa protein which is expressed within skeletal 
muscle, the heart, and at a much lower level within the CNS (Blanco, et.al., 2001). The 
Kyphoscoliosis peptidase protein (KY) contains a predicted transglutaminase/protease 
(TGN/PROT) domain between residues 171 and 282, identified through a PSI-BLAST 
database search (Blanco, et.al, 2001). Thus, placing KY in the family of 
transglutaminase-like proteins. To this day there is no sufficient evidence to claim that 
this region holds any enzymatic activity. Transglutaminases are conserved across 
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many species, most of the proteins within this superfamily are predicted to be 
enzymatically active, utilising a catalytic triad. This triad consists of a cysteine, a 
histidine, and an aspartate (Makarova, et.al., 1999), highly resembling the catalytic 
site of papain-like proteases (Anantharaman, et.al., 2001). Transglutaminase activity 
enables the catalysation of proteinase resistant isopeptide bonds, leading to the cross 
linking of proteins. These enzymes require the binding of Ca2+ in order to initiate their 
activity (Griffin, et.al., 2002). KY has homology to multiple proteins from the 
transglutaminase family, all of which contain a domain homologue to the human 
transglutaminase (Blanco, et.al., 2001). Many of the eukaryotic transglutaminases are 
thought to have been derived from ancestral proteases (Makarova, et.al., 1999), 
providing evidence that KY may contain protease activity. Conversely, some 
conflicting research has suggested conserved transglutaminase domains are not 
enzymatically active but have been re-assigned for a different role, such as mediating 
protein-protein interactions (Anantharaman, et.al., 2001). In-vivo KY is known to 
localise to the Z-disk (Beatham, et.al., 2004), likely contributing to the Z-disk 
abnormalities observed within the ky/ky mouse. 
1.4.3 KY’s Interacting protein partners 
KY has been shown to interact with several sarcomeric proteins, typically 
immunoglobulin rich proteins, which include FLNC, Immunoglobulin-like and 
fibronectin type III domain containing 1 (IGFN1), and the myosin binding protein C 
(Beatham, et.al., 2004). These proteins all have a significant role within maintaining 
muscle integrity, allowing for normal structural organisation and function. KY has 
previously been implicated as a structural protein, forming a large protein complex 
with IGFN1 and FLNC which was shown to localise to the Z-disk (Baker, et.al., 2010). 
The interaction between KY and FLNC has been extensively explored. Ky deficient 
mice and humans both show abnormal FLNC distribution, alongside large FLNC 
protein aggregates when compared to the wildtype muscles (Hedberg-Oldfors, et.al., 
2016). This highlights KY’s importance in maintaining normal FLNC distribution and 
potentially in regulating FLNC protein degradation through BAG3.  A series of co-
21 
 
transfections performed in C2C12 myoblasts also showed KY may be able to modulate 
the levels of FLNC (Beatham, et.al., 2004).  
1.4.4 Human cases of KY mutations 
In more recent years mutations of KY have been identified within patients presenting 
with novel myopathies. These patients all show a remarkable similarity to the ky/ky 
mouse, suggesting KY’s role is highly conserved between species. Ky deficient 
muscles within humans and mice both show Xin and FLNC protein aggregates. 
Histological studies within patients also revealed a huge diversity in the size of muscle 
fibers, many of which were very small with internalised nuclei (Appendix). These 
features are commonly seen within myofibrillar myopathies which are characterised 
by the formation of aggregates, and the dysregulation of Z-disk proteins (Palmio and 
Udd, 2016).  
The first reported case of a KY deficiency was seen in a seven-year-old girl. A one 
base deletion in KY resulted in a frame shift and led to a premature STOP codon. This 
KY variant was shown to be expressed within skeletal muscle; therefore, this variant 
must have encoded a non-functional truncated protein. The girl presented with walking 
difficulties, generalised muscle weakness and mild contractures within the hips, 
shoulder, and feet. She had undergone Achilles tendon elongation surgery. Tissue 
biopsies revealed muscle atrophy and extreme fiber size variability (Appendix). 
Furthermore, she had internalised myonuclei, and further studies also revealed a 
thickened Z-disk’s alongside sarcomeric disorganisation. Large protein aggregates of 
FLNC and Xin were seen, again suggesting dysregulation of protein degradation 
(Hedberg-Oldfors, et.al., 2016)  
A KY deficiency was next seen to cause a congenital myopathy within two Arab Israeli 
brothers from a first cousin marriage. A homozygous variant was shared between these 
brothers, where a premature STOP codon in exon 6 results. Both patients presented 
with muscle weakness and mild atrophy of the lower limbs. The younger brother was 
affected more severely than the older brother. The younger brother showed muscle 
weakness and atrophy which extended into his upper limbs, further to this Kyphosis 
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was shown to develop. He also showed intellectual impairment, anxiety, and impulsive 
behaviour. Cranial and spinal MRI’s revealed normal cardiological functions. 
Pathological studies of the quadriceps at 17 years of age, showed split fibers, fiber size 
variability and internalised nuclei. Interestingly, type II fiber uniformity was seen, 
conversely to type I fiber uniformity in mice. FLNC aggregation was again seen within 
these biopsies. Electron microscopy further revealed Z-disk thickening as well as an 
enlarged endoplasmic reticulum (Straussberg, et.al., 2016).  
The next reported cases of a KY mutation were identified within twelve Bedouin 
individuals, these individuals where part of the same highly inbred tribe, presenting 
with hereditary spastic paraplegia. A KY homozygous variant was identified within 
this family. This variant was caused by a disruptive single base pair insertion within 
the first exon of KY. These patients showed spasticity of the lower limbs, showing toe 
walking and equinus deformity. Within the older patient’s kyphoscoliosis was shown 
to develop, most patients showed atrophy of the tongue. Alongside a few patients who 
also showed an intellectual disability. Pathological studies revealed fiber size 
variability and centralised nuclei. High expression of this KY variant was seen within 
the muscles and to a lower level in the central nervous system (CNS). Again, a clear 
muscular pathology is observed within these cases, with patients showing muscular 
weakness and spasticity. Furthermore, most patients developed kyphosis and or 
scoliosis, further implicating muscular weakness as the primary cause of this pathology 
(Yogev, et.al., 2017).  
The final case was found within an Iranian patient who presented with myofibrillar 
myopathy. A new nonsense mutation was identified within KY. The patient was a 29-
year-old male, symptoms of muscular weakness presented at the age of 3. His lower 
limbs showed muscle weakness and atrophy, alongside having equinovarus foot 
deformity. Mild scoliosis and joint contracture where also identified. Bloods were 
taken, his serum showed abnormally high creatine phosphokinase (CPK) and lactate 
dehydrogenase (LDH). CPK is an enzyme found in the brain, heart, and skeletal 
muscles. Serum CPK can be elevated as a normal response after exercise, other causes 
include muscular inflammation and muscular dystrophy (Lasich, 2014). LDH is found 
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across your whole body, and normally rises after physical exertion. Serum LDH has 
been shown to rise in response to muscle damage and muscular myopathies (Haller 
and DiMauro, 2012). His sister also presents with generalised muscle weakness, 
alongside an aunt who had passed away.  
The cases described above all show remarkable similarities and some subtle 
differences. In all cases vast fiber size variability is seen alongside internalised nuclei 
which is a marker of regeneration. KY deficient muscles all showed a thickened Z-disk 
(Beatham, et.al., 2004), further implicating a primary involvement of the Z-disk within 
the ky/ky pathology. Further to this, patients deficient in KY show aggregation of 
FLNC and Xin. FLNC is a structural cross-linker critical for normal muscle pathology; 
mutations and dysregulation of FLNC cause severe myopathies (Leber, et.al., 2016; 
Chen, et.al., 2019). It is interesting to note the KY variant seen in the 12 Bedouin 
individuals lead to spasticity, and a lack of control of the lower limbs. The authors also 
argued that the lower expression of KY within the CNS explained the neurological and 
cognitive aspects within this pathology. It is clear from the presented cases KY has a 
distinct role in maintaining a normal muscular pathology. These cases also indicate 
KY has a significant role in maintaining normal protein regulation, shown by the 
dysregulation of protein turnover and build-up of protein aggregates. Importantly, one 
case here reported that KY localised to the sarcolemma of the muscle fiber, not the Z-
disk (Straussberg, et.al., 2016). This seems unlikely considering the high homology of 
Ky observed between species.   
1.4.5 Myofibrillar myopathies 
The phenotype seen in KY deficient patients are indicative of myofibrillar myopathies 
(MFMs), which generally are autosomal dominant myopathies with a late onset of 
progressive muscle weakness (Ruparelia, et.al., 2012). A wide variety of proteins can 
be mutated within MFMs all of which localise to the Z- disk, linking it to have a key 
role within the pathology of MFM. Common hallmarks of MFMs include muscle fiber 
breakdown, protein aggregation, and centralised nuclei. Interestingly, characterization 
of the protein aggregates determined many critical sarcomeric proteins such as FLNC, 
Titin, and BAG3 to be part of these aggregates (Ruparelia, et.al., 2012). The Z-disk 
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has been suggested to be the primary site affected in MFMs (Selcen and Engel, 2011). 
The data reviewed here suggests that the myopathy caused by KY mutation directly 
places it within the MFM category. 
1.5 Immunoglobulin-like and fibronectin type III domain containing-1 (IGFN1) 
1.5.1 Overview of IGFN1 
Immunoglobulin-like and fibronectin type III domain containing 1 (IGFN1) was one 
of the first proteins to be identified to interact with KY alongside FLNC. These 
interactions were identified using a yeast two-hybrid assay (Baker, et.al., 2010). Like 
Ky, Igfn1 is highly conserved among species. Igfn1 is specifically expressed within the 
skeletal muscle and is a complex gene, supporting many isoforms. The largest isoform 
(IGFN1) comprises an N-terminus containing three globular domains, a large 
unstructured region separating the C- and N-terminus, and a C-terminus which 
contains eight globular domains. The domain composition of IGFN1 resembles other 
sarcomeric proteins such as FLNC, which are associated with the actin cytoskeleton, 
and used to maintain protein interactions after contraction. IGFN1 has been shown to 
localise to the Z-disk and the nucleus. IGFN1 also lacks any enzymatic activity likely 
acting through the formation of protein complexes, such as the IGFN1-FLNC-KY 
complex (Baker, et.al., 2010). IGFN1 is highly expressed in atrophic conditions, and 
correlates with myostatin signalling, which induces muscular atrophy (Rahimov, et.al., 
2011). Further to this, IGFN1 was suggested to down regulate protein expression via 
an inhibitory interaction with Eukaryotic translation elongation factor 1A (eEF1A) 
during times of muscle denervation (Mansilla, et.al., 2008). DNA microarrays 
comparing gene expression from the vastus lateralis skeletal muscle in young and old 
healthy men, revealed a decrease in IGFN1 expression within the elderly (Welle, et.al., 
2003).  
Previous work found a positive correlation between IGFN1 expression and myostatin 
which is known to promote muscle atrophy (Rahimov, et.al., 2011). However, no 
direct evidence has shown that IGFN1 is capable of inducing muscle atrophy. IGFN1 
is a known interacting partner of ZAK, a Kinase family with two isoforms ZAKα and 
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ZAKβ. The ZAKβ isoform is dominantly expressed within skeletal muscle, 
overexpression of ZAKβ has been shown to increase muscle fiber size (Unpublished 
work, Li, 2016). Patients presenting with ZAK mutations, remarkably show a similar 
phenotype to that of KY deficient patients. These patients present with scoliosis, 
muscular weakness, fiber size variability, centralised nuclei, and a predominance of 
type I fibers. The typical phenotype displayed suggests that dysregulation of ZAK may 
contribute the phenotype observed within ky/ky patients. Further to this ZAK has been 
shown to be upregulated in the ky/ky mouse, providing further evidence that 
dysregulation of ZAK may contribute to the ky/ky phenotype. Recent data has also 
shown that IGFN1 can interact with the proteasomal subunits Psmd2,11 and 12 
(Cracknell, et.al., 2020). The ability of IGFN1 to localise to the nucleus and the Z-
disk, provides evidence that IGFN1 could be able to respond to stimuli in a 
temporospatial way. 
The large unstructured region IGFN1 holds is predicted to provide flexibility to the 
protein (Davey, 2019), therefore potentially allowing for a conformational change to 
occur. This conformational change could allow control over the localisation between 
the Z-disk and nucleus. IGFN1’s correlation with myostatin’s, and the ability to 
interact and modulate proteins involved within the UPS provides evidence that IGFN1 
may be involved in protein turn over, by either recruiting or promoting expression of 
proteasomal proteins. Overall, the data provided suggests that IGFN1 may have a role 
in aiding muscular atrophy. There is also good reason to believe that IGFN1 is able to 










1.6.1 Does KY contain any enzymatic activity with the TGN/PROT domain? 
Due to the high homology the TGN/PROT domain holds with active cysteine proteases 
and eukaryotic transglutaminases, it is plausible that KY may hold enzymatic ability. 
One inherent feature seen within the ky/ky pathology is Z-disk dysregulation and Z-
disk thickening. If KY holds transglutaminase activity, this may aid Z-disk 
stabilisation, through an ability to cross-link proteins with proteinase resistant 
isopeptide bonds. The strong conservation of the key amino acids required for 
enzymatic activity suggest this domain may hold enzymatic ability.  
1.6.2 Does KY’s TGN/PROT domain control Z-disk localization? 
KY is a known Z-disk associated protein, there is still a lack of evidence for the 
TGN/PROT domain to hold any enzymatic ability. The TGN/PROT domain is the 
most highly conserved region among species. Therefore, if KY does not hold any 
enzymatic ability within this region, it must be conserved to serve another function, 
such as aiding Z-disk localisation. As previously mentioned, some conserved 
transglutaminase domains are not enzymatically active but have in fact been re-
assigned for a different role such as mediating protein-protein interactions 
(Anantharaman, et.al., 2001). Therefore, it may be that KY conserves the TGN/PROT 
domain to aid Z-disk localisation.  
1.6.3 Can the Human KY localize to the Z-disk? 
The mouse KY protein has been shown to localise to the Z-disk. Little work has been 
published surrounding the human KY (hKY). Controversially, a human muscle biopsy 
showed the hKY to localise to the sarcolemma of the muscle fiber (Straussberg, et.al., 
2016). Due to the high level of conservation, and the similar pathologies seen within 
Ky deficient models it is unlikely there is a significant enough sequence difference to 
cause a drastic change to the KY protein. Therefore, it is highly likely the hKY will 




1.7 Objectives and Aims. 
KY still to this day remains highly uncharacterised and no specific role has yet been 
determined for KY within skeletal muscle. The primary aim of the project is to uncover 
the role of the highly conserved TGN/PROT domain. As the domain is highly 
conserved among species it must have a significant role within the function of KY. 
Uncovering the function of this region would give us a good insight into the function 
of KY, allowing us to further understand the method of action and the pathogenic 
mechanism contributing to the ky/ky phenotype. In order to study the TGN/PROT 
domain we will use a series of recombinant proteins, all of which contain mutations 
affecting the TGN/PROT domain. Two studies will be performed in-vivo, firstly 
assessing the ability of a series of these KY constructs to localise to the Z-disk, each 
construct having varying mutations within the TGN/PROT domain. Secondly 
assessing the ability of these constructs to rescue fibers within a new strain of ky/ky 
mouse.  
In order to determine if the TGN/PROT domain is enzymatically active, York 
Universities Proteomics department will attempt to purify protein of the full-length 
KY, and a selection of a smaller region which will include the TGN/PROT domain. 
Thus, allowing us to test the enzymatic ability of the TGN/PROT domain within KY. 
If successful we will also aim to crystallise this protein in order to determine the 
structure.  
Finally, as mentioned the hKY has been suggested to localise to the sarcolemma of a 
muscle fiber (Straussberg, et.al., 2016). The mouse KY is known to localise to the Z-
disk; thus, it is unlikely such a significant change in the protein localisation would be 
seen within the hKY. Loss of function ky/ky patients all present with Z-disk thickening, 
therefore suggesting a primary involvement of the Z-disk within the pathology. 
Furthermore, the phenotype in KY patients is highly similar to that of the ky/ky mouse. 
Thus, the evidence provided suggests the hKY is acting mechanistically similarly to 
the mouse KY, and if so should localise to the Z-disk like the mouse KY. Therefore, 
in order to better understand the human myopathies caused by loss of function KY 



























2.1 Table of Reagents 
2.1.1 Solutions and Reagents 
Reagents Formular 
PBS PBS tablets (Thermofisher, Cat #BR0014) 
PBST PBS with 0.1% Tween-20 (Sigma, Cat #P1379) 
Full Serum Growth 
medium (GM) 
DMEM (Thermofisher, Cat #31053044) with 10% 
FBS (Thermofisher, Cat #A4766) and 1% Penicillin 
Streptomycin (Gibco, Cat #15140122) 
Freezing medium  10% DMSO, 40% Serum Free Growth Medium, 50% 
FBS 
10X TBE Diluted in 1L of ddH2O: 108g of Tris base, 55g of 
Boric acid, and 7.5g of EDTA 
TAE buffer Diluted in 1L of ddH2O: 242g of Tris base , 100ml of 
0.5 EDTA, and 57.1mls of glacial acetic acid 
LB Broth  Diluted in 1L of ddH2O: 10g Tryptone, 10g NaCl, 5g 
Yeast Extract, pH 7 
LB Agar Diluted in ddH2O: (Thermofisher, Cat #CM0003) 
Polyacrylamide gels 15% polyacrylamide gels were made using 1.5mls of 
10x TBE, 6mls of dH2O, 7.5mls of 30% Acrylamide 
(Severn Biotech, Cat #20-2100-10), 150μl of 10% 
APS solution, and 15μl of TEMED 
Mowiol  6mls of ddH2O, 12mls 0.2M Tris, 2.4g Mowiol 4-88 





Antibody Concentration Supplier 
Anti-α-Actinin (EA53) 1:300 Abcam, Cat #ab9465 
Anti-WGA (Wheat  1:250 Abcam, Cat #ab17844 
 
Secondary Antibodies 
Antibody Concentration Supplier 
Anti-mouse-IgG (FITC) 1:100 Abcam, Cat #ab6717 





Primer Sequence Purpose 
Mouse Ky 
Forward 
5’ GGGGCCATTTGCAGCCTA Genotyping 






5’ CACCATGGAGCTGAAGAAG Conformation 
of correct 





2.2 Heteroduplex analysis  
Identification of heterozygous and homozygous Ky mice was done using heteroduplex 
Analysis. Heteroduplex analysis relies on the formation of heteroduplexes during PCR 
amplification, the identification of these indicates a Heterozygous mouse. Notches 
from the mice were taken post weaning by the animal facility. Notches were then 
heated at 95°C in 0.05M NaOH for 25 minutes. Neutralised with 0.08M Tris-HCL and 
0.2mM EDTA, samples were then quickly vortexed. Sonication was used to break 
down the ear notch.  
2.2.1 PCR Amplification  
PCR was used to amplify target sequences, using GoTaq green master mix (Promega, 
Cat #M7122) following the protocol provided. Primers were kindly provided by 
Gonzalo Blanco (Primer Table). We optimised the PCR protocol by changing the 
annealing temperature to 56°C. In order to verify a successful PCR amplification 1% 
agarose gels were run for 45 minutes at 80V. In order to identify the expected ~2.1Kb 
bands, we used a 1Kb DNA ladder (Biolabs, Cat #N3232L). 
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2.2.2 Polyacrylamide Gel Electrophoresis 
After confirming the presence of a PCR product, PCR samples were loaded onto 15% 
polyacrylamide TBE gels, which were used to separate heteroduplexes from 
homoduplexes. 15% polyacrylamide gels were made using 1.5mls of 10x TBE, 6mls 
of dH2O, 7.5mls of 30% Acrylamide (Severn Biotech, Cat #20-2100-10), 150μl of 
10% APS solution, and 15μl of TEMED. Gels were run overnight for 16 hours at 45V. 
Gels were then stained with SYBR safe (Invirtogen, Cat #S33102) for 15 minutes. 
Gels were imaged with a BioRad EZ GelDoc system (BioRad. Cat #1708270EDU). 
The presence of multiple bands shows us the formation of a heteroduplex as they 
migrate slower through the gels, suggesting the presence of multiple alleles. Therefore, 
single bands were read as Homozygous wildtype or homozygous ky/ky. Two bands 
indicated Heterozygous WT/ky (Figure 4). 
 
This technique effectively allowed us to identify Homozygous and heterozygous mice. 
Visual phenotyping of the colony allowed us to successfully differentiate the 
homozygous WT and homozygous ky/ky mice. 
 
Figure 4. Polyacrylamide gels loaded with PCR amplified Ky. In each experiment 1Kb 
DNA ladders were used to ensure the correct product. Furthermore 2 PCR water controls 
were used in each experiment. Heterozygous (Black writing) and homozygous (Red 
writing) mice are marked on the gels. A) Polyacrylamide gel 1. Gel loaded with four test 
samples (3 Females; 1 Male). B) Polyacrylamide gel 2. Gel loaded with seven test samples 
(4 males; 3 Females). 
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2.3 DNA Cloning 
The ky DNA constructs were amplified for cell transfections and In-vivo muscle 
electroporations. For successful electroporation high DNA concentrations 
(~1000ng/ml) were required, whilst cellular transfections required a lower DNA 
concentration (~300ng/ml). Therefore, we used a mixture of Maxi- and Mini-Preps, 
adjusting for the required DNA concentrations. 
2.3.1 Transformation 
Transformations were performed using Agilent competent cells and the provided 
reagents (Agilent, Cat # 200131), the protocol was followed precisely. Changes 
included LB Broth being used instead of SOC medium. Cells were thawed on ice, 50ul 
of cells were transferred to pre-chilled round bottomed falcon tubes and 0.850ul of B-
Mercaptoetanol was added, cells were incubated on ice for 10 minutes. 2ul of DNA 
construct was then added to the tubes and left to incubate on ice for 30 minutes. Cells 
and constructs were heat shocked at 42°C for 45 seconds, then 450ul of preheated 42 
°C LB broth was added. Cells were then incubated at 37 degrees shaking at 225rpm 
for an hour. Cells were then spread on premade agar plates, which contained the 
relevant antibiotics and left overnight. All plates contained ampicillin, as all of our 
constructs had a selective ampicillin resistance. 
2.3.2 DNA-preps 
Single colonies were selected from overnight cultures and inoculated in a starter 
culture of 5 ml LB medium containing 1X the relevant antibiotic, this culture was 
incubated at 37°C on a shaker at 200rpm for 8 hours. Depending on the prep being 
undertaken, the starter culture diluted down in pre-warmed LB medium. The starting 
culture for mini preps was transferred into another 5mls of LB medium and left 
overnight. The starting culture for maxi-preps was diluted 6-fold into 30mls of 
prewarmed LB and left overnight. This culture was then transferred into ~800mls of 
prewarmed LB medium and left overnight. All cultures were left at 37°C on a shaker 
at 200rpm. For larger cultures 2L conical flasks were used.  
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Cultures were pelleted, then resuspended in resuspension solution from the provided 
Maxi- or Mini-prep kit. The Kit protocols were followed precisely. Whilst performing 
the Maxi-prep we also performed the optional DNA precipitation step to further 
concentrate our DNA to acquire high yields of DNA (~1000ng/ml). A nano drop was 
then used to measure DNA concentration.  
2.4 Cell culture 
2.4.1 Proliferation 
C2C12 myoblasts and COS-7 fibroblasts were cultured in Dulbecco’s modified Eagles 
medium (DMEM) (Thermofisher, Cat #41966-029), supplemented with 10 % foetal 
bovine serum (FBS) (Thermofisher, Cat #A4766) and 1% penicillin / streptomycin 
(Gibco, Cat #15140122) (full serum DMEM). Cells were left incubated at 37 °C and 
5% CO2.  
Cells were split weekly before confluency was reached using 1% trypsin solution. 
Prior to splitting, cells were washed with pre-warmed PBS. Trypsin was added and left 
for 10 minutes in the incubator. Post incubation most cells would be detached, trypsin 
would be neutralised through full serum addition. Cells were then split to ~20% of 
their original confluency. 
2.4.2 Freezing 
Cells were routinely frozen for cell preservation. Cells would be trypsinised as 
described above, then removed, placed in a 15ml falcon tube and centrifuged at 
1200rpm for 12 minutes. The supernatant would be removed, and the resulting pellet 
would be resuspended in either 1ml (T25 flask) or 3mls (T75 flask) of freezing media 
(Reagents Table), depending on the flask size. This would be immediately aliquoted 
into 1ml cryotubes and transferred into the -80°C freezer or liquid nitrogen. 
2.4.3 Transfections 
C2C12 myoblasts and COS-7 fibroblasts were cultured on glass slides within 24 well 
plates, myoblasts where seeded at 70-80% confluency before transfections. In order to 
transfect the ky constructs we used Genjet Invitro DNA transfection reagent 
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(SignaGen, Cat #SL100488). Following the protocol provided for 24 well plates and 
the appropriate cell line, cells were transfected. The transfection reagent was removed 
12~18 hours post-transfection, being replaced with fresh full serum DMEM. 
Transfection efficiency was then checked 48 hours post transfection using a 
fluorescent microscope. 
2.4.4 Fixation and Immunofluorescence. 
Immunofluorescence analysis on C2C12 and COS-7 cells was carried out. Cells were 
fixed and mounted from 24 well plates onto glass slides before analysis. 
Cells were washed twice with phosphate buffered saline (PBS) (Thermofisher, Cat 
#BR0014), then fixed using 4% paraformaldehyde (PFA) (Sigma, Cat #P6148) diluted 
in PBS for 15minutes. PFA was then removed and the cells were washed twice with 
PBS and once with dH2O. Cells where mounted on slides, with mowiol (Fluka, Cat  
#81381) and 4’,6-diamidino 2-phenylindole (DAPI) (Sigma, Cat #D9542) at 1:1000 
dilution to stain the nuclei.  
Cellular imaging took place on a Leica epifluorescent inverted laboratory LED 
microscope (Leica, Cat #DM IL LED) 
2.5 In-Vivo Experiments. 
2.5.1 In vivo electroporation 
An hour before the electroporation procedure mice were injected with 50µl of 
hyaluronidase (Sigma, Cat #SLBX4632) (0.4U/µl diluted in 0.9% saline), alongside 
being given pre-operative analgesia in this case Bupavet (50μg/ml), 2 µl of Bupavet 
was administered per gram of mouse weight. 
Mice were placed in an anesthetising box with 4% isoflurane diluted in O2, mice were 
left until deeply anesthetised. Mice were transferred to a continually anesthetised 
rodent face mask and a toe pinch reflex was used to insure deep anaesthetic. 
Throughout the procedure mice were kept on a heating pad maintained at 37°C. In 
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order to expose the tibialis anterior (TA) a subcutaneous incision was made. DNA 
constructs with a concentration above 1000ng/µl were injected directly into the TA 
(Figure 5.A), then three mm electrodes were placed within the muscles (Figure 5.B).  
 
Pulses were delivered using a NEPA21 machine (Nepagene, Japan). Initially three 50-
msec-long pulses at 80V followed by three more pulses of the opposite polarity were 
administered at each injection site at a rate of one pulse per sec. Mice were sacrificed 
eight days post electroporation.  
Mice were sacrificed by a schedule one kill using cervical dislocation or rising CO2. 
The TA/EDL of the mice was dissected. Muscles which had undergone electroporation 
would be fixed in 4% PFA for 15 minutes, then transferred to PBS. The whole muscle 
would be placed under a fluorescent microscope to check for a successful 
electroporation. If successful we would clearly see transfected fibers (Figure 6).  
Figure 5. Mouse electroporation on a wildtype mouse. A) DNA microinjection. 20ul of a 
specified DNA construct would be injected directly into the exposed TA muscle. B) 
Electroporation of the TA. A current would be run through the TA using an electrode, 




Successfully electroporated muscles would then been snap frozen in liquid nitrogen 
cooled isopentane (Honeywell, Cat #M32631), then stored in the -80°C. Muscles 
which were to undergo histological analysis did not require fixation by PFA, instead 
they were instantly snap frozen in liquid nitrogen cooled isopentane.  
2.5.2 Animal research ethics 
All animal procedures were carried with approval from the University of York Ethics 
committee and followed the UK Animals (Scientific Procedures) Act 1986 
Amendment Regulations 2012. All procedures were performed by Gonzalo Blanco 
(Project licence number: P3FF2D943) within an approved establishment (Licence: 
X323ED8C8). 
2.5.3 Muscle sectioning 
Frozen muscles were removed from the -80 and kept on dry ice before sectioning with 
a cryostat (Leica, Cat # CM1520). Muscles were either sectioned cross sectionally or 
longitudinally depending on what we were looking for. Sections would typically be 
Figure 6. Whole Mount Images of successfully electroporated muscle fibres. Whole 
mount images where taken at a 4x magnification. The bottom left-hand corner of each panel 
shows the construct used. A) Electroporated tdTomato. B-E) Electroporated KY 
constructs. Each individual KY construct was tagged with tdTomato giving the red 
fluorescence. F) Electroporated hKy-eGFP.  
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around 12-14μm in width, being condensed on the superfrost adhesion slides 
(ThermoFisher, Cat #J1820AMNT). Sections were then placed in the -80 for storage, 
before mounting and staining.  
 
2.5.4 Immunofluorescence of mouse muscle sections 
In order to identify the Z-disk within the longitudinal sections, we needed to stain the 
α-actinin. Sections were thawed from the -80 freezer, then rehydrated with PBS. 
Sections were then permeabilised with 0.1% triton diluted in PBS for 5 minutes, 
sections were then washed twice with PBS. Post washing sections were blocked in 4% 
BSA (Diluted in PBS). Again, two washes were performed with PBS. Next the primary 
antibody EA53 (Abcam, Cat # ab9465) was added at a 1:300 dilution in PBS and left 
to incubate at 4°C overnight. Three 5-minute washes in PBS were undertaken before 
secondary antibody incubation. We used two secondary antibodies; FITC and TRITC 
(Reagents Table), both were left to incubate for two 25minutes at room temperature, 
as per the manufacturer’s instructions. Finally, two five-minute PBS Washes and a 
ddH20 washes were undertaken before mounting with DAPI diluted in mowiol. 
In order to be able to identify individual fibers within the muscle cross-sections, we 
stained with Wheat Germ Agglutinin (WGA), which binds sialic acid and N-
acetylglucosaminyl residues, commonly used for imaging of plasma membranes. The 
same method of thawing and rehydration was used before incubating sections for 20 
minutes in WGA (1.400 diluted in PBS). Post WGA staining slides where washed 3 
times with PBS and once with ddH2O. Again, slides were mounted with DAPI diluted 
in mowiol. 
All slides were imaged wither using a Leica epifluorescent inverted laboratory LED 







Cross sectional sections of the TA were thawed from the -80 freezer, 15 minutes before 
Hematoxylin and Eosin H&E treatment. Slides were fixed in acetone for 10s before 
being transferred into Hematoxylin (Sigma, Cat# 290629) for 2 minutes. After 
Hematoxylin treatment the slides were washed for 1 minute with running water. The 
slides were then transferred to Scotts water for 1 minute, and immediately after they 
were washed with running water for 1 minute. After washing the slides were 
transferred into Eosin (Sigma, Cat# 861006) for 45 seconds. Immediately they were 
placed in 70% ethanol for one minute, then 100% ethanol for another minute. Finally, 
the slides were placed in Histoclear for a further minute, before mounting. Slides were 
then mounted with  
Histological images where taken with a Lecia optical microscope (Lecia, Cat 
#DM2500), using the Insight 2Mp Monochrome FireWire Digital camera to capture 
images. This camera uses the SPOT basic software.  
2.7 Enzymatic Tests 
2.7.1 Transglutaminase Enzymatic test 
The SIGMA-ALDRICH transglutaminase assay kit (Sigma, Cat #CS1070) was used 
to test for transglutaminase activity. The protocol was followed precisely when 
performing this test. We used a 1.2ug sample of the full-length protein due to 
limitations on the amount of protein. With the small domain we used a sample of 10ug, 
the maximum recommended amount of protein. Appropriate blanks were used, and the 
positive control derived from a guinea pig liver (provided by kit), was diluted in the 
appropriate buffer as per the manufacturer’s instructions. A Dynex technologies MRX 
II Plate reader was used to measure the absorbance at 450nm. 
2.7.2 Protease Enzymatic test 
The ThermoFisher Scientific Pierce Protease Assay Kit (ThermoFisher, Cat#23263) 
was used to test for protease activity. Again, the protocol was followed precisely. The 
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full-length KY was tested at 50ug/ml, with an appropriate blank and positive control 
at the same concentration. The small domain KY and MBP control were tested at 
500ug/ml, again with an appropriate blank and positive control at the same 
concentration. The positive control TPCK trypsin was provided by the kit. A Dynex 
technologies MRX II Plate reader was used to measure the absorbance at 450nm. 
2.8 KY Protein Purification 
All protein production was performed by the University of York Protein Production 
laboratory, with special thanks to Jared Cartwright and Rebecca Preece for their 
ongoing support and hard work.  
2.8.1 Sample Prep 
An o/n culture from transformed colonies was grown in 500ml of auto induction 
medium + Kanamycin (30ug/ml) at 37°C for 2hrs the 20°C in a shaker. The resulting 
solution was then pelleted down at 5,000rpm for 10mins. Protein pellets were 
resuspended in 100mls of extraction buffer which included a protease inhibitor 
cocktail. The suspension was sonicated five times for 30 seconds, being put on ice 
between pulses. Samples of 20ul were taken for use as a total gel sample. Cell debris 
was removed by centrifugation at 17,000g for 10mins at 4°C before 20ul being taken 
for a soluble gel sample. 
2.8.2 Column Prep 
Purification columns were prepped by adding 1.2mls (for full length KY) or 5ml (for 
MBP-KY(aa160-285)) of nickel beads to a tube. Beads were washed with 7 CV dH2O 
whilst not disturbing the beads. 5CV His Buffer A was added to equilibrate the beads 
and allowed to settle, carefully the liquid was removed. Again, this procedure was 
repeated 7 times. The beads were then transferred to two 50ml falcon tubes, His buffer 
A was utilised to aid the transfer to the falcon tubes, any excess His buffer A was 
removed after the transfer. 100mls of lysate was then added to the two falcon tubes of 
beads, 50mls in each. The falcon tubes were then incubated for two hours at 4°C with 
mixing. Falcon tubes were then Centrifuged at 1000g for 1 minute at 4°C. Excess 
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liquid was then removed, leaving the beads and approximately 2mls excess liquid in 
each tube. At this point 20ul was taken to be used as the flowthrough gel sample. 
A 1.2ml (for full length KY) or 5ml (for MBP-KY(aa160-285) column was then 
packed with the remaining 2ml of flow through and the beads. By gravity flow with 
the flow dripped through, the remaining beads were washed with His Buffer A. 
Gradient elution was performed on a BioRad NGC purification system (BioRad). The 
gradient elution of 0-100% with His buffer B occurred over 10 column volumes where 
1ml fractions were collected. UV read outs for each fraction were obtained and to 
confirm the presence of the protein, SDS-PAGE gels were run. Anti His blots were 
also performed for the full-length KY protein.  
2.8.3 Analytical Size Exclusion 
Analytical size exclusion was performed on the full-length KY protein. 100ul from the 
peak fraction of the His purification was loaded onto the AKTA 10 purification system 
using a 500ul superloop. A superdex 200 increases 10/300 GL column was used. An 
SDS-PAGE gel was run to confirm which fractions the KY protein was present in.  
2.8.4 Size Exclusion 
Size exclusion was used on the small MBP domain. The peak fractions were 
concentrated from the His Purification to approximately 4mls, using a 50ml falcon 
spin concentrator. This was then loaded onto the BioRad NGC purification system 
(BioRad, Cat #6286) using a 10ml superloop. A superdex 200 pg 16/60 size exclusion 
column was used. SDS-PAGE gels were run allowing identification of the fraction in 







Table 1 . Buffers used throughout protein purification and analysis. Left column 
shows the buffers, whilst the right shows their composition. 
Buffer  Composition 
Extraction Buffer 100mM Tris-HCl pH 8.0, 0.1% Tween20 
His Buffer A (Full 
length protein) 
50mM Tris-HCl pH 8.0, 300mM NaCl, 30mM Imidazole 
His Buffer B (Full 
le0ngth protein) 
50mM Tris-HCl pH 8.0, 300mM NaCl, 500mM Imidazole 
His Buffer A (Small 
domain) 
20mM Sodium Phosphate pH 7.4, 300mM NaCl, 30mM 
Imidazole 
His Buffer B (Small 
domain) 
20mM Sodium Phosphate pH 7.4, 300mM NaCl, 500mM 
Imidazole. 
Size Exclusion 
Buffer (Full length 
protein) 
50mM Tris-HCl pH 8.0, 300mM NaCl. 
Size Exclusion 
Buffer (Domain) 
20mM Sodium Phosphate, 300mM NaCl 
 
 
2.9 Statistical analysis and Figure preparation. 
2.9.1 Quantification of C2C12 speckled phenotype 
A total of four slides were transfected providing us with 4 biological replicates for 
each construct. Each slide produced a large number of images, in order to count the 
cells quickly and accurately a specific method was used. Images were converted to 8 
bits, then pushed to the threshold using the (Figure 7. A & B). The particle analyser 
was then used to count the number of cells. In order to count the speckled phenotype, 
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the contrast and brightness of the image was lowered drastically to a set point. At this 
point it clearly allowed us to identify the cells showing large aggregates (Figure 7.C). 
 
Data was then compiled in an excel file, for each image the number of cells showing 
a phenotype was recorded, alongside the total number of cells for that image. Using 
this data, a percentage of cells showing the phenotype was calculated using the 
equation below. 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡𝑎𝑔𝑒 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑤𝑖𝑡ℎ 𝑎 𝑝ℎ𝑒𝑛𝑜𝑡𝑦𝑝𝑒 =
𝑁𝑏 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑤𝑖𝑡ℎ 𝑎 𝑝ℎ𝑒𝑛𝑜𝑡𝑦𝑝𝑒
𝑇𝑜𝑡𝑎𝑙 𝑁𝑏 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠
 𝑋 100 
The data gathered from each biological replicate was then compiled for each construct. 
A shapiro test was used to test normality, then a one-way ANOVA was used to 
compare the means. 
2.9.3 Statistical tests performed on Enzymatic Assays 
Both the Transglutaminase and Protease assays measured the end result as an 
absorbance at 450nm, the readout was proportional to the amount of enzymatic 
activity. Thus, in both cases three repeats for each test sample would be obtained. 
Overall, these assays were both run a minimum of three times, each revealing similar 
end results. Normal distribution was assumed due to the low replicate number. A one-
way ANOVA allowed us to make valid comparisons between the means of each data 
 
Figure 7. Counting of cells and cells showing a speckled phenotype. A) Conversion of 
images to 8 Bit. Images were converted to 8 bits. B) Images pushed to a threshold. Images 
then underwent the particle analyzer which had set parameters. C) Adjusted contrast and 
Brightness highlighting aggregates. After adjusting the contrast and brightness the 
aggregates were clearly visible, due to a brighter presence on the image. 
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set. A post hoc Tukey’s Test was also run for both enzymatic assays, backing up the 
findings of the ANOVA.  
2.9.4 Quantification of colocalization  
Again, four slides were co-transfected with the relevant constructs. This provided us 
with 4 biological replicates for each construct. Each slide produced ~5 images with 
co-transfected cells, due to the lower level of co-transfection seen. 
Fiji was used to measure the level of co-localisation between the two proteins. Firstly, 
merged images were split into their individual channels, blue (DAPI), green, and red. 
After the channels were split into 8-bit images (Figure 8.A), the green channel was 
pushed to the threshold (Figure 8.B), and the cells expressing both constructs were 
selected, and stored in the ROI. After selecting the relevant cells, they were checked 
against the original image, ensuring all the co-transfected cells were selected. We 
performed the co-localisation test using the Coloc-2 plugin for Fiji, specifically using 
Costes threshold regression method (Costes, et.al., 2004) was used. The region of 
interest for the test was specified through stored regions on the ROI manager, and the 
data was then collected as a spearman’s rank correlation, the plugin also produced an 
image highlighting area of colocalization (Figure 8.C). 
 
The collected data was then compiled into excel. In all cases the data was merged. A 
one-way ANOVA was run comparing the means of each construct. This data was then 
Figure 8. Co-localisation measurements between two proteins. A) Conversion of red 
channel images to 8 Bit. These images where subsequently pushed to the threshold to 
specify areas for the coloc2 test to run, these were stored within the ROI manger. B) 
Conversion of green channel images to 8 Bit. C)Resulting output after coloc-2 test. The 
areas highlighted in white show areas of high Co-localisation.  
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represented as a box plot, allowing visualisation of outliers and how the data is 
dispersed. 
2.9.5 Complementation quantification. 
Successfully electroporated muscle fibers were quantified using Fiji (Schindelin, et.al., 
2012). Cross sectional muscle fiber sections were either stained with WGA or were 
overexposed in a FITC filter, allowing visualisation of muscle fibers membranes. 
Images were then taken, and fiber size was measured using image J. Firstly the scale 
bar was set from the corresponding image. All transfected fibers were drawn around 
and stored in the region of interest (ROI) manager (Figure 9.A). Then using the ROI 
manager, each fiber’s cross-sectional area was measured, and used to create an average 
fiber size for transfected fibers. Secondly the same procedure was used to measure the 
Untransfected fibers giving us an average size of Untransfected fibers (Figure 9.B).  
 
The data gathered was then used to create a ratio, which was used to compare 
transfected fiber size to untransfected fiber size. A ratio was used as it gave us a simple 
 
Figure 9. Quantification of cross-sectional area for transfected and untransfected fibers. 
A) Measurements taken from transfected fibers. Clearly transfected fibers were drawn 
around and stored in the ROI manger, each having its unique identification number. B) 
Measurements taken from untransfected fibers. Measurements would be taken from a 





way of seeing if a construct was increasing or decreasing the fiber size in the ky/ky 
mouse. If the Ratio > 1 the fiber size has increased. If the Ratio < 1 it has decreased.  
 
𝑅𝑎𝑡𝑖𝑜 =
𝑇𝑟𝑎𝑛𝑠𝑓𝑒𝑐𝑡𝑒𝑑 𝐹𝑖𝑏𝑟𝑒 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 
𝑈𝑛𝑡𝑟𝑎𝑛𝑠𝑓𝑒𝑐𝑡𝑒𝑑 𝐹𝑖𝑏𝑟𝑒 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 
 
 
The Ratio also allows for a valid comparison between mice as it normalises the 
untransfected fiber size for each mouse leg to 1.  Therefore, we are able to perform 
statistics on multiple repeats. For each construct we had at least 3 replicates. In this 
case a one-way ANOVA, normal distribution was assumed due to the small replicate 
size.  
2.10 In-Silico Analysis  
2.10.1 Sequencing and Alignment 
BLAST (Altschul, et.al., 1990) was used to locate the hKY variants. The BLASTx tool 
takes a nucleotide sequence and compiles an output of highly similar sequences. Using 
the mouse Ky nucleotide sequence taken from ENSEMBL Ky-201 
(ENSMUST00000039390.5)), a BLASTx was run, specified to look at sequences 
within Homo sapiens (Taxid: 9609). This allowed us to identify Homo sapiens ky 
variants.  
BLAST was also used to compile a collection of Ky homologues from a vast repertoire 
of species. The Ky DNA sequences were acquired using BLASTx. Retrieved 
sequences were subsequently imported into the Molecular Evolutionary Genetic 
Analysis (MEGA-X) software (Kumar, et.al., 2018). MEGA-X was used to convert 
these DNA sequences into protein sequences using the Standard genetic code. These 




2.10.2 Phylogenetic Analysis 
Phylogenetic analysis was performed using MEGA-X. Within all analysis the Jones, 
Taylor, and Thorton (JTT) model of evolution was selected (Jones, et.al., 1992). Using 
the aligned Ky homologues, a neighbour joining tree was produced. This was produced 
using the PHYLOGENY tab, where the construct/test Neighbour joining tree option 
was selected, the parameters used are shown below (Figure 10.A). The produced tree 
was then edited and modified within MEGA-X.  
MEGA-X was also used to estimate the rate of evolution at each protein site. Using 
the RATES tab within MEGA-X, the Estimate Position-by-Position Rates (Maximum 
likelihood) option was run using aligned KY protein homologues (Figure 10.B). The 
data output for the rate of evolution at each site was produced, this data was then 
collated in excel. The relative rate at each nucleotide site was then used to produce 
graphs and figures. 
 
  
Figure 10. The parameters used within MEGA-X statistical tests. Both tests used the same 
substitution model. A) Parameters of Phylogeny Reconstruction. Selected from the 
PHYLOGENY tab B) Parameters of Estimate Rate at Each Site (Maximum Likelihood). 










Chapter 3: In-vitro 











3.1 Overexpression of Ky variants within C2C12 mouse myoblasts 
The current evidence suggests that the conserved TGN/PROT domain plays a 
significant role within KY’s mechanistic action. To further investigate this, multiple 
mutagenised Ky constructs were utilised, previously produced by George Atkinson 
during his master’s project. These constructs were originally produced from 
pDEST47-Ky-tdTomato (Ky-td), the full-length mouse KY tagged with tdTomato. 
These constructs each contain various mutations within TGN/PROT domain. These 
constructs are as followed: pDEST47-Ky-SM-tdtomato (Ky-SM) which holds a single 
Cystine to alanine (C[225]A) substitution within the first conserved residue of the 
catalytic triad. pDEST47-Ky-TM-tdtomato (Ky-TM) where all three conserved 
residues are substituted with alanine (C[225]A, H[267]A, and D[282]A). Finally, 
pDEST47-Ky-DEL-tdtomato (Ky-DEL) which had the whole TGN/PROT domain 
removed (DEL[217-285]) (Figure 11).  
 
The mutations and deletions were mapped using ENSEMBL Ky-201 
(ENSMUST00000039390.5). An empty vector encoding tdTomato was used as 
control. The three catalytic residues held within the TGN/PROT domain, are known 
to be critical for enzymatic ability. The Ky-SM and Ky-TM which have these residues 
substituted with alanine will likely show no enzymatic ability. Previous work has 
Figure 11. Mutagenised KY Constructs. pDEST47-Ky-tdTomato encodes the wild type 
full length mouse KY protein, the conserved residues of the catalytic triad within the 
TGN/PROT domain is shown (orange box), while tdTomato (red box) is attached via the 
C-terminus.  pDEST47-Ky-SM-tdTomato holds a single (C[225]A) substitution in the 
catalytic triad of the conserved TGN/PROT domain. pDEST47-Ky-TM-tdTomato holds a 
triple substitution in all three conserved residues of the catalytic triad (C[225]A, H[267]A, 




shown replacement of these residues with alanine greatly reduces enzymatic activity, 
shown by mutated catalytic residues within other TGN/PROT domain from similar 
proteins (Carter and Wells, 1988). Therefore, these constructs are predicted to have no 
enzymatic activity, if indeed KY is enzymatically active. 
It has been predicted that a large number of eukaryotic proteins with transglutaminase 
domains have lost their enzymatic ability. These regions have likely evolved to 
mediate protein-protein interactions (Anantharaman, et.al., 2001), which may explain 
how KY interacts with IGFN1 and Filamin C in the IGFN1-FLNC-Ky protein complex 
(Baker, et.al., 2010). To investigate the functions of the TGN/PROT domain, C2C12 
proliferating myoblasts were transfected with the aforementioned KY TGN/PROT 
domain mutants and assessed for protein localisation and cellular morphology when 
overexpressed. GenJet invitro transfection reagent was used to transfect the C2C12 
myoblasts followed by incubation for 48 hours to allow each construct to express, 
before finally fixation and mounting with mowiol mounting agent and DAPI.  
All KY constructs showed cytoplasmic expression, further observation revealed a high 
proportion of transfected myoblasts contained large cytoplasmic aggregates (Figure 
12.B-E) when compared to the control, pDEST47-tdtomato (Figure 12.A). ImageJ was 
utilised to quantify these aggregates whereby a precise method was used to count the 
number of cells displaying these protein aggregates (Methods).  
A one-way ANOVA showed each KY construct had a significantly increased amount 
of cytoplasmic aggregates compared to the tdTomato control. Further to this Ky-DEL 
showed a small significant increase in the percentage of aggregates seen when 
compared to the other KY constructs (Figure 12.F). No other morphological changes 






3.2 Purification of Ky Protein constructs.  
To understand the role of the conserved TGN/PROT domain, we needed to determine 
whether this domain is still enzymatically active. The conserved TGN/PROT domain 
still contains the catalytic residues Cystine, Histidine, and Aspartate which form the 
catalytic triad needed for enzymatic activity. This high level of conservation, seen 
specifically at the catalytic residue sites, suggest that KY may still hold enzymatic 
ability. 
To test whether KY holds enzymatic abilities within the TGN/PROT domain, it was 
decided to purify different KY protein constructs. These constructs consisted of the 
full-length protein and a selection of smaller intermediates all of which contained the 
conserved TGN/PROT domain. Two constructs showed a good promise of being 
solubilised; a small MBP tagged version which ranged from amino acid (aa) 160-285 
 
Figure 12. Overexpression of KY constructs within C2C12 myoblasts. A-E) Different 
Ky constructs expressed within C2C12 myoblasts. The Texas red channel reveals the Ky 
construct used. The Overlay with DAPI is shown on the right. A scale bar is shown in the 
bottom right-hand corner. F) Quantification of phenotype. A Bar graph is shown with 
different constructs. Error bars are shown, P= ‘***’<0.001. ANOVA result: F= 104.2, 




containing the TGN/PROT domain (MBP-KY(aa160-285)), and secondly a His tagged 
full-length Ky protein (KY) also showed a good level of solubilisation (Figure 13). In 
order to control for the MBP tag on the MBP-KY(aa160-285), purified MBP was also 
produced, for use as a control 
 
3.3 Transglutaminase Assay’s on Purified KY protein. 
Purified protein was tested with a transglutaminase assay kit. This kit tests the ability 
of proteins to catalyse the formation of a covalent bond between a free amine group of 
poly-L-lysine and the γ-carboxamide group of biotin-TVQQEL-OH. If the test protein 
holds any transglutaminase activity biotin is immobilized to the plate, then detected 
using Streptavidin-Peroxidase and 3,3′,5,5′-Tetramethylbenzidine Liquid substrate. 
The amount of biotin adhered is detected using 450nm wavelength. The amount of 
biotin detected is then proportional to the enzymatic ability of the test protein.  
The test specified 1-10 µg of test protein was needed, each condition had 3 repeats. 
The yield of the purification of the MBP-KY(aa160-285) protein was very high, 
therefore 10μg of protein was used per repeat. The purification of the KY protein was 
not as efficient, therefore only 1μg of test protein could be used in each repeat. The 
MBP control was used at 10μg for each test. An active transglutaminase originating 
from a guinea pig liver was provided by the kit and used as a positive control. Each 
test was incubated at room temperature for 30 minutes as per manufacturer’s 
instructions. 
Figure 13. Schematic diagrams of purified KY constructs. Two constructs are shown the 
His tagged full-length KY and the MBP tagged small TGN/PROT domain. Both constructs 
were tagged via their N-terminus. Each protein tag has been highlighted, the TGN/PROT 
domain in both constructs is highlighted in orange. The numbers indicate the reflected 




Results from the transglutaminase activity test indicated that KY does not have any 
transglutaminase activity (Figure 14). The transglutaminase enzymatic activity of both 
KY and MBP-KY(aa160-285) was significantly lower than the positive control. 
Statistical analysis from a one-way ANOVA showed a significant difference between 
the positive control and each of the KY purified proteins. KY, MBP-KY, and the MBP 
control all showed significantly lower optical density of Biotin than their buffer 
controls.  
3.4 Protease Assay’s on Purified KY protein. 
Again, purified protein was tested for protease enzymatic activity using the Pierce 
Protease Assay Kit. The test uses succinylated casein and trinitrobenzenesulfonic acid 
(TNBSA). Succinylated casein is native casein that has been treated with succinic 
anhydride to block primary amines on the surface of the protein. Proteases cleave the 
succinylated casein at peptide bonds, exposing the primary amines. TNBSA is then 
used to detect exposed primary amines, producing an orange colour.  
 
Figure 14. KY’s TGN/PROT domain holds no transglutaminase enzymatic activity. In 
both cases enzymatic activity was measured throughout the detection of a substrate at 
450nm. Error bars are shown alongside the significance difference, P= ‘***’<0.001. A) 
Transglutaminase assay on MBP-KYaa(160-285). The different constructs tested are as 
shown. A MBP control was used due to the MBP tag include on the MBP-KYaa(160-285). 
ANOVA result: F= 28.43, df = 3, p-value = 5.1x10 -3. B) Transglutaminase assay on KY 
protein. The different constructs tested are as shown. ANOVA result: F= 31.02, df = 2, p-
value = 6.86x10-4. 
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For statistical significance, three repeats were used for each construct. Again, the 
maximum amount of protein was used if available. MBP-KY(aa160-285) was tested 
at 500 µg/ml, with the control and MBP buffer at the same concentration. Whilst KY 
was tested at 50 µg/ml with the positive control, a Trypsin standard provided by the 
kit, at the same concentration. In both cases the appropriate buffers were also tested. 
Each test was incubated at room temperature for 20 minutes as per manufacturer’s 
instructions. Then Optical density, and therefore the level of orange colour produced 
in the reaction, was measured using the 450nm wavelength. 
 
 
The results from the protease assay show that the Ky protein does not have any 
protease activity (Figure 15). The measured activity of MBP-KY(aa160-285) and the 
full KY protein were both significantly lower than the positive control. The little 
variance observed between both proteins provides further confidence in these results. 
Furthermore, this experiment was repeated twice with similar results. 
 
Figure 15. KY’s TGN/PROT domain does not contain any protease activity. A) Protease 
assay for MBP-KY. The different tested constructs are shown.  B) Protease assay for 
purified KY protein.  In both cases enzymatic activity was measured throughout the 
detection of a substrate at 450nm. Error bars are shown alongside the significance 
difference, P= ‘***’<0.001. A) Protease assay for MBP-KY(aa160-285). The different 
constructs tested are as shown. A MBP control was used due to the MBP tag include on 
the MBP-KY(aa160-285). ANOVA result: F= 788.4, df = 4, p-value = 1.77x10 13. B) 
Protease assay for purified KY protein. The different constructs tested are as shown. 










Chapter 4: In-vivo 













4.1 Histological analysis of the Ky deficiency seen within the C3 strain of mice. 
The original homozygous ky/ky mouse arose due to a sporadic mutation within the 
BDL strain of mice first reported by Dickinson and Meikle (1973). This mutation led 
to the development of spinal curvature (kyphoscoliosis) leading to postural changes 
caused by postural muscle weakness. The ky/ky mice typically show pathology within 
slow contracting postural muscles such as the soleus. It has been shown that these 
muscles undergo a single postnatal phase of fiber degeneration and regeneration 
(Bridges, et.al., 1992). Furthermore, Ky deficient mice show dramatic shifts in the type 
of MHC and MLC isoforms expressed within slow muscles, which leads to a complete 
shift to type I fibers within the soleus (Blanco, et.al., 2001). Here it was suggested this 
shift in fibers type is an adaptive shift due to the low muscle to body weight ratio.  
For this project, a new strain of ky/ky mice were derived from the C3H background of 
mice. These ky/ky mice may therefore be different to the original ky/ky mice. Early 
observations showed similarly overt features when compared to the original ky/ky BDL 
strain, these mice could be easily recognised post weaning. In most cases, mice were 
quickly identified due to their smaller size, and inability to perform a normal placing 
response test in which ky/ky mice were unable to reach towards a ledge, due to 
weakened paraspinal and postural muscles (Appendix). Interestingly within the C3H 
background the male ky/ky mice seemed to exhibit a more severe pathology. In the 
most severe cases mice would exhibit whole body tremors, a drastically smaller size, 
and exhibit an increased respiratory rate.  
Histological analyses were performed to identify phenotypic differences between the 
BDL and C3H genetic backgrounds, and furthermore to investigate if in C3H 
background the males had a worst phenotype. The soleus was obtained from both male 
and female wildtype and ky/ky mice. The soleus was chosen as it is a postural slow 
contracting hind-limb muscle and is known to be severely pathological in the ky/ky 
mutant. Mice were taken at 8 weeks old; the TA and soleus were dissected which 
allowed easy access to obtain sections to observe the soleus. These sections were then 





Figure 16. Histological analysis of the soleus of Wildtype and ky/ky mice. A) 
Haematoxylin and eosin-stained sections from wildtype and ky/ky mice soleus. The row 
shows the soleus taken from wildtype and Ky mice. The bottom row shows the soleus taken 
from female wildtype and Ky mice. B) Quantification of the percentage of internalized 
nuclei from ky/ky mice and wildtype soleus. No statistical analysis was performed as these 






Due to limited time only one replicate was taken for comparisons of WT and ky/ky 
male and female mice. Mice were taken at 8 weeks. As expected, H&E staining 
revealed a highly pathological soleus for both the female and male ky/ky mice (Figure 
16.A). The first thing noticed was the extreme fiber size variability when compared to 
the ordered nature of the WT soleus. A WT soleus will typically have homogeneous 
fibers with consistent cross-sectional area. This was observed in both male and female 
WT soleus muscle sections. Conversely, the ky/ky mice show a vast heterogeneity of 
extremely small fibers alongside much large sized fibers. Unfortunately, due to limited 
repeats it was not possible to gather the data. But this phenotype is clearly seen within 
these fibers (Figure 16.A).  
Next, we observed that a good proportion of the ky/ky fibers showed centralised nuclei, 
which is a typical hallmark of fiber regeneration. The presence of a high proportion of 
extremely small fibers further indicated that the muscle had been undergoing 
regeneration. To quantify these fibers undergoing regeneration, the number of fibers 
showing centralised nuclei were counted as a percentage of the total number of fibers 
in the muscle (Figure 16.B). Results showed both WT female and male mice had very 
few fibers showing centralised nuclei. When compared to WT mice, ky/ky mice had 
an increase in the number of centralised nuclei, which was observed to be higher in 
the female than the male.  
Overall, there is a clear pathology within the soleus of this new strain of ky/ky mice 
when compared to wildtype mice. The pathology is highly reminiscent of the original 
pathology seen within the BDL strain of ky/ky mice. 
4.2 In-vivo localisation of recombinant KY proteins. 
KY is a known Z-disk associated protein, absence of this protein from the Z-disk is 
known to cause a multitude of abnormalities such as Z-disk thickening (Beatham, 
et.al., 2004). The region within the KY protein which aids targeting to the Z-disk is 
yet to be elucidated. It has previously been theorised the TGN/PROT domain may aid 
targeting of KY to the Z-disk. Previously electroporated Ky-DEL in the tibialis 
anterior (TA) of a mouse showed a more diffuse pattern of expression when localising 
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to the Z-disk, when compared to the clear striations of Ky-td which localise clearly to 
the Z-disk (Unpublished work, Jokl, 2018). This data suggested that the conserved 
TGN/PROT domain may have a role in targeting KY to the Z-disk. Further being 
backed up by the evidence that many eukaryotic transglutaminases have likely evolved 
to serve another function (Anantharaman, et.al., 2001).  
In order to assess the ability of the TGN/PROT domain to target KY to the Z-disk, 
different KY constructs would be electroporated into mouse TA muscles, thus 
allowing visualisation of localisation. Using the mutagenised KY constructs (Figure 
11) we tested each construct’s ability to localise to the Z-disk. We theorised that were 
the TGN/PROT domain critical for Z-disk targeting, mutations within the region 
would result in less/absent localisation to the Z-disk, and the full deletion would likely 
potentially show no attachment to the Z-disk at all. The TA of wildtype mice was 
electroporated with these constructs, due to the fact it is easy to access for 
electroporation and dissection. 
Mice had hyaluronidase injected into each leg which was to undergo electroporation, 
this aids the breakdown of the ECM, thus allowing for a higher electroporation 
efficiency (Cemazar, et.al., 2012). Mice underwent the electroporation procedure 
through a surgical protocol allowing for an accurate and repeatable method of 
electroporation (Methods). Mice were then left for 8 days to express recombinant 
proteins. Mice were then sacrificed, and the TA was dissected. 
Frozen muscles were sectioned longitudinally. Post sectioning, one slide was mounted 
with DAPI in order to identify regions of interest. It was clear that striations could be 
visualised for each construct except for tdTomato. Therefore, to confirm that these 
striations were visualised at the Z-disk, sections were stained with EA53 which is an 
anti-α-Actinin antibody. Sarcomeric α-actin is a vital component of the Z-disk and is 
therefore a good biomarker to identify the Z-disk. This would allow us to confirm that 
fiber striations seen with the KY constructs were indeed localised to the Z-disk, post 




Figure 17. Z-disk localization of mutagenised KY constructs. Longitudinal sections of 
electroporated muscles stained. Columns from left to right: The first column is an α-Actinin 
stain highlighting the Z-disk. The Texas-red filter detects different KY construct used within 
each row. The Magnification column shows the area within the white box for each 
corresponding construct. The final column shows an Overlay of the α-actinin, Texas red, 
and DAPI. A scale bar is also shown in the overlay column. Row A) Electroporated 
tdTomato. tdTomato showed a diffuse expression profile along the fiber. Row B) 
Electroporated Ky-td. Ky-td shows extremely clear striations, which overlay with the α-
actinin. Row C) Electroporated Ky-SM. Again, clear striations are seen with the fiber also 
lining up with the α-actinin. Row D) Electroporated Ky-TM. The striations within this 
construct are slightly harder to see but are still present. Row E) Electroporated Ky-DEL. 
Clear striations are seen throughout the fiber, lining up with the α-Actinin. 
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Results showed that each KY construct did in fact localise to the Z-disk (Figure 17). 
Compared to tdTomato each construct shows very clear striations, which co-localise 
with the α-actinin, showing Z-disk localisation. Interestingly the diffuse pattern 
observed previously with Ky-DEL was not observed here, whereby this construct 
produced a very clear striation pattern. This result suggests that the loss of the 
TGN/PROT domain does not seem to affect the localisation of KY to the Z-disk. All 
other KY constructs showed clear Z-disk localisation. Thus, it is unlikely the 
TGN/PROT domain is aiding Z-disk targeting.  
4.3 In vivo complementation of a ky/ky deficiency 
Unpublished work has suggested that the KY protein can induce a hypertrophic 
response to rescue atrophic muscle fibers within ky/ky muscles (Unpublished work, 
Jokl, 2018). Interestingly when Ky-td is overexpressed in wildtype muscles, no 
hypertrophic response is observed, suggesting KY protein amount does not correlate 
with the level of hypertrophy (Unpublished work, Jokl, 2018). Also showing that KY 
is not a regulator of hypertrophy but is necessary to maintain the muscle and initiate a 
hypertrophic response. Surgical overload within wildtype muscles causes an adaptive 
response whereby a change in the type of MHC expressed is observed, alongside 
muscle fiber hypertrophy. No hypertrophic response is observed in ky/ky mice when 
surgically overloaded (Blanco, et.al., 2001). Hence, KY must have a significant role 
in inducing a hypertrophic response, indicating that it may be important for 
mechanosensing and the Z-disk.  
The relevance of the conserved TGN/PROT domain still remains elusive, therefore we 
wanted to determine whether the TGN/PROT domain is important for fiber size rescue 
in ky/ky mice. To investigate this, the mutagenised TGN/PROT domain KY constructs 
previously used would be electroporated into the TA muscles of ky/ky mice, and 
evaluated for their ability to rescue normal fibre size.  
Furthermore, this experiment can also be used to test by an independent method the 
importance of the conserved catalytic residues within the TGN/PROT domain. We 
have previously reported that mutations within the TGN/PROT domain are not 
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sufficient to alter Z-disk localization (Figure 17). Therefore, if we assume the 
mutations within these KY constructs are sufficient to remove or limit any enzymatic 
activity, we can utilise these to test if enzymatic ability is needed to induce a 
hypertrophic response. If a hypertrophic response is seen with enzymatically dead 
versions of Ky (Ky-SM & Ky-TM), we can conclude that the enzymatic ability and 
the catalytic triad is not needed to induce a hypertrophic response. 
Again, we chose to electroporate the TA of ky/ky mice. The constructs, tdTomato, Ky-
td, Ky-SM, Ky-TM, and Ky-DEL were electroporated in ky/ky mice using the same 
surgical procedure and pre-treatment with hyaluronidase. Mice were then left for 8 
days allowing for construct expression and any subsequent phenotypic changes within 
the muscle to become apparent, before being euthanised. The TA muscles were 
dissected, frozen in liquid nitrogen-cooled isopentane. Cross sections of the TA muscle 
were obtained using a cryostat to allow for analysis of the fiber cross-sectional area. 
Finally, sections where imaged, and quantified (Methods). 
The cross-sectional area of transfected and untransfected fibers was measured using 
ImageJ. The ky/ky phenotype shows vast fiber size variability, so comparisons between 
mice were impossible without normalisation. In order to make valid comparisons 
between different mice we opted to represent the difference in cross-sectional area 
between the transfected and untransfected fibers as a ratio (Methods). If the normalised 
value for the transfected fibers is above 1, then the average fiber size is greater than 
the untransfected. Conversely, if it is less than 1 the fiber size has reduced in 
comparison to the untransfected fibers.  
In each case a minimum of three biological replicates were used. The tdTomato control 
showed a much higher electroporation efficiency than other constructs (Figure 18.A). 
All KY constructs showed a much lower electroporation efficiency when compared to 
eGFP, likely due to the mKY constructs' larger sizes (Figure 18.B-E). A one-way 
ANOVA was used on the ratio averages and showed a significantly higher cross-
sectional areas for Ky-td, Ky-SM, and Ky-TM when compared to the control 
untransfected fibers, tdTomato and Ky-DEL. Neither Ky-DEL or tdTomato showed 
62 
 
any statistical difference when compared to the untransfected fibers indicating there 
was no change from the original size pre-electroporation. No Statistical difference was 





These results indicate that the mutations of the conserved catalytic residues (Cystine, 
Histidine, and Aspartate) do not affect the ability of KY to induce hypertrophy in ky/ky 
muscle fibers. Interestingly, the removal of the whole conserved TGN/PROT domain 
does have a significant effect on the ability to induce hypertrophy, as the Ky-DEL 
construct is unable to induce the same hypertrophic response as the WT, Ky-SM, and 
Ky-TM counterparts. Therefore, we conclude that the whole domain has a role in 




Figure 18. Enzymatically dead versions of Ky can induce a hypertrophic response within 
the muscles of Ky deficient mice. Each row shows a different Ky construct which has been 
electroporated into Ky/Ky mice. Columns from left to right: The FITC fluorescent filter 
was used to highlight cellular membranes. The Texas-red filter was then used to detect the 
different Ky constructs overexpressed in Ky/Ky mice. Finally, the last column is an overlay 
of the two filters including DAPI. A scale bar is shown at the end of each row and 
corresponds to each construct used A) tdTomato electroporated into Ky/Ky mice. 
Overexposure of the FITC filter allowed visualization of individual fibers. B) Ky-td 
electroporated into Ky/Ky mice. Again, the FITC filter was overexposed to outline of the 
fibers.  C) Ky-SM electroporated into Ky/Ky mice. WGA was detected in the FITC filter 
to outline the cell membranes of individual fibers D) Ky-TM electroporated into Ky/Ky 
mice. WGA was detected in the FITC filter E) Ky-DEL electroporated into Ky/Ky mice. 
WGA was detected in the FITC filter. F) Quantification of electroporated fiber size 
compared to untransfected Ky/Ky fibers. A ratio was developed to represent a change in 
fiber size. If the ratio is higher than 1 the fiber has grown. A Box plot represents each Ky 
construct, compared to untransfected fibers. Data underwent a one-way ANOVA allowing 
valid comparisons of the ratios. Neither Ky-DEL or tdTomato are significantly different 























5.1 In-silico human KY analysis 
One report describing a patient with a KY myopathy suggested that the human KY 
(hKY) localizes to the sarcolemma (Straussberg, et.al., 2016), contradicting previous 
research which shows KY is a Z-disk associated protein (Beatham, et.al., 2004). 
Therefore, we wanted to unequivocally identify the subcellular localization of hKY in 
vivo. The hKY and mouse ky (mKy) share a sequence identity of ~ 91 % and are 94% 
similar; thus, it is unlikely the small sequence differences observed within their 
alignment would produce a significant change in the protein’s function or localization.  
To find a suitable hKY candidate a pBLASTp of the mKy was run against homo 
sapiens. Results showed all isoforms had greater than 80% homology with the mKy. 
The multiple hKY isoforms identified all showed the exact same amino acid starting 
sequence as the mKy (MELKKD). Intriguingly, one hKY Isoform (hky X5) which also 
displayed a high homology with mKy had the starting sequence of the mKy aligned 
upstream of the start site for hKY X5. Further analysis showed that the hKY X5 
contained an extra 59 amino acids preceding the MELKKD start sequence of the hKY 
(Figure 19.A) and mKy. This newly identified region started with a Methionine which 
was in frame with the rest of the protein.   
Interestingly, using nuclear localization signal predicting software (Nguyen, et.al., 
2009) we found that this region contained a nuclear localization signal (NLS). The 
extra region including the MELKKD motif, was run through multiple NLS predictors 
(Nguyen Ba, et.al., 2009; Jhih-Rong Lin, et.al., 2012). Both predictors gave us 
readouts for an NLS within this extra region, with cut-off scores above 0.9. The NLS 
motif giving the highest cut-off score was RRPGRK (Figure 19.B) (Appendix). This 
newly identified extra sequence was predicted to enable the hKY X5 isoform to localize 








Nuclear localization signal 
A 
B 
Figure 19 Protein sequences of Homo sapiens hKY-X5 against the hKY. A protein alignment 
shows the extra region identified within the N terminus of hky-X5. B) KY isoform X5 nuclear 
localization signal. The extra sequence identified was found to contain a nuclear localization 
signal (Orange text). The starting Methionine is highlighted in red along with the second 
Methionine. The (Blue text) has the highest NLS cut of score above 0.9. 
67 
 
Next, we wanted to look at what other species may contain this extra sequence. A 
tBLASTn search was run using the extra region found in hKY-X5. Results of the 
BLAST search showed that only primates conserved this sequence out of all other 
mammals (Figure 20.A). All identified Primates showed conservation of the first 
Methionine of the extra region, including the NLS in frame with the original start 







To assess conservation of this region, a collection of similar genes were identified 
through a pBLASTp using the full length hKY X5 isoform as the sequence of interest. 
The homologous sequences were a series of Ky variants from different species. Using 
MEGA-X these sequences where aligned and used to build a phylogenetic tree using 
the Newic format (Hehenberger, 2018). The polygenetic analysis revealed primates 
diverge from a common ancestor and constitute their own group (Figure 20.B).  
 To further understand the origins of this primate conserved region, extensive searches 
were run on ensemble and BLAST looking for conservation of this region within any 
other species. A tBLASTn search was run using the extra region containing the NLS 
and no hits were found within fish. Interestingly, some species showed partial 
conservation of this region (Figure 20. A). The only examples where the entire region 
with the NLS was conserved were, American Beavers, Dogs, and Guinea pigs although 






























Figure 20. Conserved nuclear localization signal within primates shows high genetic 
divergence within other species. A) A group of Aligned ky Sequences. The beginning 
sequences from a collection of ky sequences taken from multiple species. B) Circular 
Newic phylogenetic tree from a collection of ky homologues from different species. The 
tree was generated using MEGA-X. Primates are highlighted in red showing their distinct 
group. C) Evolution rate at each protein site of aligned KY homologues. Using the Jones, 
Taylor, and Thornton model (JTT) model of evolution the rate of evolution at each protein 
site was predicted. Five gamma categories gave the relative rate. The TGN/PROT domain 




protein. Thus, concluding that this region containing the NLS sequence is solely 
conserved within primates. 
Finally, we wanted to look at the rate of evolution at each amino acid site in an 
alignment of multiple KY homologues. The rate of evolution at a given site is 
calculated, which maximizes the probability of the given alignment under the selected 
model of evolution. In this case the Jones, Taylor, and Thornton (JTT) evolution model 
(Jones, et.al., 1992) was used.  
Results indicated a higher level of protein evolution at the beginning of the protein, 
shown by a logarithmic trendline (Figure 20.C). As you move along the protein, levels 
of evolution decrease. It is likely this reflects the fact that many species other than 
primates have either lost or only show partial conservation of the extra region which 
holds the NLS, while conserving the majority of the KY protein which starts at the 
second Methionine with the motif MELKKD. A gap at 200-220 amino acids represents 
a gap within the aligned data, where a single KY protein, derived from the papio 
Anubis (Olive Baboon), included an extra amino acid sequence, which no other species 
contain. This species being within the primates also included the extra region with the 
NLS.  
5.2 In vitro overexpression of human KY 
To assess the subcellular localisation of hKY and test whether the newly identified 
NLS could cause nuclear localisation, a new construct of the hKY X5 isoform was 
ordered from GenScript. The hKY X5 was cloned into the mammalian expression 
vector pcDNA3.1(+)-C-eGFP through a HindIII/BamHI cloning strategy. This 
subsequently produced the new hKY vector pcDNA3.1-hKy-eGFP (hKy-eGFP) 
(Figure 21). Two restriction digests were used to confirm the correct cloning. Finally, 
sequencing was used to confirm the flanking sequences of the cloning site, both of 




To test the subcellular localisation of hKy-eGFP within myoblasts, lipofectamine 
transfections within C2C12 myoblasts were undertaken. We wanted to test whether 
the hKY-X5 would localise to the cytoplasm, similarly to the mKY within a 
proliferating C2C12 myoblast, or whether the predicted NLS sequence was sufficient 
to cause nuclear localisation, C2C12 myoblasts were grown to ~80% confluency, 
transfected with hKy-eGFP using GenJet In-vitro Transfection reagent according to 
the manufacturer’s instructions. Cells were left to incubate for 48 hours before fixation 
and mounting. Cells were then imaged using fluorescent microscopes.  
Results showed nuclear and cytoplasmic expression (Figure 22). All cases of 
cytoplasmic expression were observed as a normal diffuse pattern. Conversely the 
nuclear expression showed two variations; one variation showed a “speckled” pattern 
of expression (Figure 22.A&B), while the other showed a diffuse expression across 
the whole nucleus, similar to that observed in the cytoplasm (Figure 22.C&D).  
Overexpression of hKy-eGFP within C2C12 myoblasts comes in two patterns. Nuclear 
and cytoplasmic expression is clear in both cases, but the differences lie within the 
nucleus. One pattern shows diffuse expression across the whole nucleus. Conversely 
the other shows a “Speckled” pattern of expression. 
 
 
Figure 21. Cloned human KY isoform X5 (hKy-eGFP). The human ky isoform X5 was 
cloned in the vector pcDNA3.1-(+)-eGFP  the cloned region shown above. The Highlighted 
blue region on the left indicates the extra region which contains the NLS, the two-start 
methionine’s are shown above. The light blue box indicates the conserved TGN/PROT 
domain shown are the conserved Cysteine, Histidine and Aspartate. eGFP is attached to 





5.3 Co-localisation of IGFN1_V1 and the human KY 
The Immunoglobulin-like and fibronectin type III domain containing 1 (IGFN1) 
protein was one of the first proteins to be identified in a yeast-two-hybrid assay to 
interact with KY alongside other sarcomeric proteins such as FLNC (Beatham, et al., 
2004). IGFN1 is specifically expressed within skeletal muscle and is a complex gene, 
supporting many isoform variants. IGFN1 lacks any enzymatic activity, therefore it is 
likely that it initiates protein complex formations. One such formation is the IGFN1, 
FLNC and KY complex, which has been suggested to provide structural support at the 
Z-disk (Baker, et.al., 2010). IGFN1 is known to localise to the nucleus and is able to 
translocate to the cytoplasm (Baker, et.al., 2010).  
As previously seen, expression of the hKY in C2C12 myoblasts led to a nuclear 
localisation, showing in some cases a “speckled” pattern of expression (Figure 22). 
 
Figure 22. Cytoplasmic and nuclear localization of pcDNA3.1-hKy-eGFP. A-B) 
pcDNA3.1-hKy-eGFP transfected into C2C12 myoblasts. pcDNA-hKy-eGFP is detected 
using a FITC filter. Whilst DAPI is detected using a DAPI filter. A-B) Nuclear protein 
aggregates are seen showing a “speckled” pattern of expression. C-D) Cytoplasmic 
Expression is seen, whilst still showing nuclear expression.  
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The pattern seen was similar to that of IGFN1_V1_tdTomato when overexpressed 
within COS7 myoblasts (Figure 23). To test if both proteins showed nuclear or 
cytoplasmic colocalisation or affected each other's localisation, a co-transfection with 
both the hKy-eGFP and IGFN1_V1-tdTomato was performed. 
 
In this transfection, C2C12 myoblasts were transfected with pDEST47-IGFN1_V1-
tdtomato (IGFN1_V1-tdTomato), a smaller isoform of IGFN1 without the disordered 
middle region, which has a higher transfection efficiency. GenJet transfection reagent 
was used to co-transfect IGFN1_V1-tdTomato alongside hKy-eGFP into C2C12 
myoblasts. Appropriate controls were set up: IGFN1_V1-tdTomato was transfected 
alongside pDEST-eGFP, whilst hKy-eGFP was co-transfected with pDEST47-
tdTomato. Post-transfection, myoblasts were left to express the constructs for 48 hours, 
then fixed and mounted with DAPI.  
Observations of co-transfected myoblasts indicated that hKy-eGFP and IGFN1_V1-
tdTomato were colocalising (Figure 24. A-I). Large colocalised complexes formed 
within the nucleus, whilst cytoplasmic expression seemed more diffuse.  ImageJ was 
then used to quantify protein colocalization. Images were subjected to a specific 
method to test colocalization. The Coloc2 plugin was utilised within ImageJ, Coloc2 
uses Pearson’s correlation coefficient, with costes method (Costes, et.al., 2004).  
Results showed a high level of co-localisation of hKy-eGFP and IGFN1_V1-
tdTomato, indicated by a high Pearson’s correlation coefficient score, alongside 
 
Figure 23. Nuclear localization pattern of IGFN1_V1. IGFN1_V1 transfected into COS-
7 fibroblasts. A) Phalloidin stain highlighting the actin. B) pDEST47-IGFN1_V1-eGFP 
expression profile. C) Overlay of the phalloidin stain, IGFN1_V1, and DAPI. A scale 




Figure 24. Colocalization of pcDNA3.1-hKy-eGFP and pDEST47-IGFN1_V1-
tdTomato. A-I) Fluorescent images of co-transfected IGFN1_V1 and hKy-eGFP. Rows 
consist of different co-transfected constructs; each construct is shown in bottom left of 
each panel. The right column consists of an overlay of both constructs and DAPI. A scale 
bar is shown in each overlay and corresponds to that row J) Box plot of Co-localization 
between co-expressed proteins. Pearson correlation coefficient (no threshold) was used 
to quantify co-localisation. The median is shown as the middle line inside the box, the 
lower and upper quartile are shown by the upper and lower boundaries of the box. The 
lines indicate the range of the data, outliers are shown, P= ‘***’<0.001. ANOVA result: 
F value = 55.66, df =54, p-value=0.0063. K) Pie chart of the distribution of co-localised 




having a small variance (Figure 24. J). Both controls also showed significantly lower 
Pearson’s correlation coefficients and indicated near to no co-localisation. Further to 
this both showed a much higher variance compared to hKy-eGFP and IGFN1_V1-
tdTomato. 
A count was performed to give an indication as to where the aggregates of hKy-eGFP 
and IGFN1_V1-tdTomato were forming. Three possibilities were available: nuclear 
localisation, cytoplasmic localisation or both nuclear and cytoplasmic. Results showed 
a large amount of these aggregates localised to the nucleus (Figure 24. K). Second to 
that, aggregates were observed in both the nucleus and cytoplasm. Lastly a very small 
number of aggregates were observed only within the cytoplasm. 
The results here show clear colocalised aggregates between hKy-eGFP and 
IGFN1_V1-tdTomato, most of these colocalised aggregates form within the nucleus. 
Statistical analysis further supports a high level of colocalization between these two 
constructs. In both co-transfection controls, the expression profile of the hKy-eGFP 
and IGFN1_V1-tdTomato are highly comparable. 
5.4 Co-Transfection of IGFN1_V1 and the mouse KY 
The mKY does not contain an NLS and has never been observed within the nucleus. 
Therefore, we wanted to test whether IGFN1_V1-tdTomato alone could cause nuclear 
translocation of the mKY. 
The same method for transfection was used, as previously stated, but pDEST47-
IGFN1_V1-tdtomato was swapped for pDEST47-IGFN1_V1-eGFP, as the Ky-td 
(pDEST47-Ky-tdTomato) contained tdTomato. pDEST47-IGFN1_V1-eGFP and Ky-
td were co-transfected into C2C12 myoblasts. Additionally, pDEST47-IGFN1_V1-
eGFP was co-transfected alongside tdTomato and Ky-td was co-transfected with 
pDEST47-eGFP as controls. Post transfection, myoblasts were left to express the 
constructs for 48 hours, fixed, then mounted with DAPI. 
No clear colocalization could be seen between Ky-td and pDEST47-IGFN1_V1-eGFP 
(Figure 25.A-C). The typical cytoplasmic expression profile of Ky-td was seen, and 




Figure 25. Co-expression of pDEST47-mKy-tdTomato and pDEST47-IGFN1_V1-
eGFP. A-I) Fluorescent images of co-transfected mKy-tdTomato and IGFN1-eGFP. 
Rows consist of different co-transfected constructs; each construct is shown in bottom left 
of each panel. The right column consists of an overlay of both constructs and DAPI. Scale 
bars are shown in the bottom right-hand corner of each row. J) Box plot of Co-localization 
between co-expressed proteins. Pearson correlation coefficient (no threshold) was used to 
quantify co-localisation. The median is shown as the middle value inside the box, the lower 
and upper quartile are shown by the box. The lines show the maximum and minimum 




showed its typical “Speckled” pattern of expression (Figure 23). Again, the Coloc2 
plugin for image J was used to analyse colocalization utilising the Costes method 
(Costes, et.al., 2004) (Methods). Results show a low level of colocalization between 
all colocalised constructs, with no significant difference between each group (Figure 
25.J).  
Results here suggest that Ky-td and pDEST47-IGFN1_V1-eGFP do not colocalise, as 
no visible colocalised aggregates were observed with the data analysis revealing a low 
Pearson’s correlation coefficient. Furthermore pDEST47-IGFN1_V1-eGFP is unable 
to induce nuclear translocation of Ky-td. These results confirm previous observations 
indicating that the mKY is a cytoplasmic protein (Baker, et.al., 2010). 
5.5 In Vivo localisation of human KY 
In-silico analysis and In-vitro experiments have revealed the hKY X5 isoform contains 
an extra region, in which a functional nuclear localisation signal is present (Figure 19 
& 22). It is yet to be confirmed whether this protein can localise to the Z-disk. Due to 
the high homology with the mouse Ky, it is highly likely Z-disk localisation will be 
observed along with nuclear localisation, when overexpressed in-vivo in fully 
differentiated skeletal muscle.  
To test this theory, we electroporated hKy-eGFP into mouse TA muscles, using the 
same surgical method as before, eGFP was used as a control for hKy-eGFP. Post-
electroporation, mice were left for 8 days to recover and express the recombinant 
proteins. After 8 days, mice were sacrificed, and the TA was dissected and frozen in 
liquid nitrogen-cooled isopentane. Longitudinal muscle sections of 12 μm were taken, 
immunostained, and mounted with DAPI. The Z-disks were again marked with an 
EA53 antibody against α-Actinin. High magnification images were then taken using a 
fluorescent microscope (Figure 26.A-L).  
Images of hKy-eGFP electroporated fibers showed clear Z-disk striations, which 
overlayed perfectly with the α-actinin. These results suggest that like the mKY, hKY 
X5 too is able to localise to the Z-disk. When compared with eGFP, which also shows 
some faint striations (Figure 226D-F), it is clear there is a significant difference 
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between the patterns of hKy-eGFP and eGFP. The striations seen within electroporated 
eGFP fibers are likely an artefact, due to the Z-disk being such a prominent structure 
within differentiated fibers. Furthermore, nuclear localisation was also observed with 
hKy-eGFP. Higher magnification images also revealed a “speckled” pattern of 
expression seen in most nuclei (Figure 26.M-O) similar to that which was observed in 






It is interesting to note that the expression profile observed with the hKy-eGFP highly 
resembles the in vivo expression profile of electroporated IGFN1_V1-tdTomato, 
which also shows nuclear and Z-disk localisation (Figure 24).  
Here we have seen that hKy-eGFP is able to localise both to the Z-disk and myonuclei 
in fully differentiated skeletal muscle. The eGFP tag does not affect localisation of the 
protein exhibited by the different expression profile of the eGFP control. Furthermore, 
the profile observed with hKy-eGFP resembles the expression pattern of 
electroporated IGFN1_V1-tdTomato (Figure 27). This data, alongside what we 
previously knew regarding the interaction of KY and IGFN1 in vivo, suggests that 
there is most definitely a role for the interaction of these two proteins, which is not 
exclusive to the myoplasm, it is just waiting to be discovered. 
 
Figure 26. pcDNA3.1-hKy-eGFP localizes to the Z-disk and the nucleus in vivo. 
Longitudinal sections of electroporated wildtype muscle fibers. The relevant a scale bar is 
shown, corresponding to the panels within that row A-C) Electroporated eGFP. The left 
panel shows α-actinin highlighting the Z-disk, the middle panel shows electroporated 
eGFP. The final panel shows an overlay image of the two images including DAPI. D-F) 
Magnified images of A-C. Magnified images are highlighted in the original part of the 
image taken the white box. G-I) Electroporated hKy-eGFP. The left panel shows α-actinin 
highlighting the Z-disk, the middle panel shows electroporated hKy-eGFP. The final panel 
shows an overlay with DAPI. J-L) Magnified images of G-I. White box represents 
magnified area. M-O) Low exposure images of electroporated hKy-eGFP. Low exposure 
allowed visualization of the nuclear localization. The left panel shows DAPI, the middle 













Figure 27. IGFN1_V1 localises to the Z-disk. Longitudinal sections of IGFN1_V1 
electroporated wildtype muscle fibers. Each column shows the indicated construct, the α-
Actinin was stained with an EA53 antibody. The bottom row shows an enlarged section of 
the fiber indicated within the white box. A relevant a scale bar is shown for each 

























The primary aim of this thesis was to gain a better understanding of the mechanism by 
which KY acts, through defining a definitive role for the highly conserved TGN/PROT 
domain. The secondary aim of this thesis was to explicitly define the subcellular 
localisation of the hKY, as a previous report has suggested the hKY was localising to 
the sarcolemma of a muscle fiber (Straussberg, et.al., 2016).  
6.1.1 KY does not contain any enzymatic activity within the conserved 
TGN/PROT domain 
The specific residues (Cysteine [225], Histidine [267], and Aspartate [282]) forming 
the catalytic triad within KY’s TGN/PROT are conserved among species. These 
residues are required for enzymatic ability (Carter and Wells, 1988), and as previously 
discussed, suggest that KY may hold transglutaminase or protease enzymatic activity. 
Here full length purified KY protein and MBP-KY(aa160-285) have both been tested 
for enzymatic activity. Protease and transglutaminase assays performed on both KY 
and MBP-KY(aa160-285) suggest that KY has lost any potential enzymatic abilities 
(Figures 14 & 15). Furthermore, the complementation studies performed on KY’s 
TGN/PROT domain mutants (Figure 18) would also suggest that enzymatic ability is 
not needed for its mechanistic action. Thus, Ky-TM which had all three catalytic 
residues substituted to alanine, would have likely lost any potential enzymatic ability 
(Carter and Wells, 1988), and yet was able to rescue fiber size in ky/ky mice. Thus, 
suggesting that these individual residues and in turn enzymatic activity isn’t required 
for KY protein function. Collectively this data provides strong evidence that KY is not 
enzymatically active, and that replacement of the conserved catalytic residues has no 
effect on the overall function of the resulting protein.  
The formation of catalytic triads is known to be dependent on the distance between the 
catalytic residues. Other enzymatically active eukaryotic transglutaminases which 
contain the transglutaminase catalytic triad consisting of Cystine, Histidine, and 
Aspartate all conserve 23 amino acids between there Histidine (H) and Aspartate (D) 
catalytic residues. The homo-sapien and mus musculus (Mouse), TGM family of 
proteins (UniProt, #P22735) and the coagulation factor XIII protein (UniProt, 
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#P00488), all have 23 amino acids between Histidine and Aspartate, whilst conversely 
KY only contains 15 amino acids between Histidine and Aspartate (UniProt, 
#Q8NBH2). This could cause a significant disruption within the shape of the active 
site and thus prevent enzymatic activity from occurring. One interesting observation 
is the fact the catalytic residues have been conserved throughout evolution. It has been 
shown that these specific residues are not required for the rescue of ky/ky muscle fibres, 
and do not serve any enzymatic function. Therefore, the question remains as to why 
these specific residues have been conserved, as they seem to serve no apparent function 
within the KY protein.   
6.1.2 KY’s TGN/PROT domain is not required for Z-disk localisation 
KY has been shown to be a Z-disk protein (Beatham, et.al., 2004), highly conserved 
among species. The Ky homologues all hold a TGN/PROT domain, which we now 
know to not be enzymatically active. As KY’s only distinguishable feature, it was 
hypothesised that the TGN/PROT domain was causing Z-disk localisation. Here we 
have shown this not to be the case, and therefore indicating that the region causing Z-
disk localisation is conserved elsewhere within the protein. Looking at the amount of 
evolution along the KY protein (Figure 20.C), the C-terminus appears to have evolved 
the least. Therefore, the domain controlling Z-disk localisation is likely to be contained 
within the C-terminus, due to the higher level of conservation compared to the rest of 
the protein. 
6.1.3 The human KY can localise to the Z-disk 
Previous reports have suggested that the hKY localises to the sarcolemma of the 
muscle fiber (Straussberg, et.al., 2016). Being a highly conserved protein, we 
predicted that the hKY, would localise to the Z-disk. This thesis has shown that 
primates contain an atypical version of the Ky gene, holding an enclosed nuclear 
localisation signal within an extra 49 amino acids upstream of the original start site. 
Here it has been unveiled that the hKY localises to the Z-disk like its counterparts, but 
also localises to myonuclei within a fully differentiated muscle fiber and myoblasts. 
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The data here has clearly shown that the human KY is capable of localising to the Z-
disk. 
6.2 Overview 
This thesis has once again highlighted the complex nature of KY’s role within muscles. 
This elusive protein has evolved down two separate pathways; primates conserving a 
NLS signal, while other mammals seem to have removed this NLS. Ky is known to be 
imperative for normal muscular function shown by the severe pathology seen within 
the ky/ky mouse and the human Ky myopathies, the similarities between these 
phenotypes also highlight the conserved function of KY in primates and other 
mammals. Here we have shown the TGN/PROT domain is integral to the function of 
KY. Complementation experiments show that when the whole TGN/PROT domain is 
removed, KY is unable to rescue fiber size through hypertrophy. Conversely, when 
wildtype KY is electroporated into ky/ky muscle, rescue occurs through hypertrophy. 
Thus, the TGN/PROT domain must have an integral role within KY’s mechanism of 
action to maintain normal muscle pathology. 
Muscular hypertrophy is essential to muscular health and is a normal response to 
functional overload of a muscle. To date most of the signalling cascade which allows 
for muscular hypertrophy has been identified, although the initiating signals remain 
elusive and highly debated (Wackerhage, et.al., 2019). The ky/ky mouse has been 
shown to lack a hypertrophic response (Blanco, et.al., 2001), thus KY was identified 
as a regulator of the hypertrophic response. However, a direct link between KY and 
hypertrophy had not been established. The mKY has never been seen within the 
nucleus and is not known to interact with any proteins involved within induction of 
hypertrophic pathways. The finding of a functional NLS within primates’ KY locus 
now provides evidence that KY itself may be able to modulate hypertrophic pathways, 
due to a functional nuclear link. KY is known to interact with a multitude of sarcomeric 
proteins (Beatham, et.al., 2004), such as IGFN1 and FLNC. Like many other 
sarcomeric proteins, KY localises to the Z-disk, where it has been implicated to 
provide structural support to the Z-disk, through forming large protein complexes 
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(Baker, et.al., 2010). The clear myofiber pathologies seen within ky/ky mice and the 
human myopathies highlight the critical role of KY within maintaining sarcomeric 
stability. These pathologies also implicate the Z-disk as the primary site affected. The 
Z-disk is a known site of intracellular signalling and has been suggested to sense and 
respond to stretch and mechanical overload (Luther, 2009; Knöll, et.al., 2011). Within 
the ky/ky pathology, thickened and abnormal Z-disks are commonly seen (Beatham, 
et.al., 2004). This thickening of the Z-disks might be an adaptive response to try and 
further aid sarcomeric stability or conversely may reflect the adaptive switch to type I 
muscle fibers, a common hallmark of the ky/ky pathology. Type I muscle fibers are 
known to have wider Z-disks (Luther, et.al., 2003). 
In the broader context, KY’s association with the Z-disk has led to the hypothesis that 
KY is being used for stretch sensing (Blanco, et.al., 2001), which allows for a response 
to mechanical overload. If KY is not present within muscles, the myofibers are unable 
to undergo a hypertrophic response. In wildtype muscles, mechanical overload and 
stretch induces vast changes to cellular morphology, typically occurring through 
hypertrophy. In order for these changes to occur, the damage that stretch induces, or 
the stretch present at the Z-disk during the time of mechanical overload must be 
detected and responded too. This response is absent in ky/ky mice. Therefore, the 
evidence reviewed suggests that KY is being utilised to detect stretch, or the damage 
produced from mechanical overload, and thus allows for muscular adaptation via 
hypertrophy.  
6.3 KY’s TGN/PROT domain 
A specific function for KY’s TGN/PROT domain still remains unclear, yet it is vital 
for the function of KY. Therefore, this region must serve a critical function 
underpinning KY’s mechanism. As we know, KY’s TGN/PROT domain is not 
enzymatically active, thus we can assume that similarly to other eukaryotic 
transglutaminases, KY has repurposed the function of this domain (Anantharaman, 
et.al., 2001). In this case potentially mediating KY’s interactions with other sarcomeric 
proteins, and allowing for the formation of complexes, such as the IGFN1-FLNC-KY 
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complex (Baker, et.al., 2010). Therefore, if the TGN/PROT domain is mediating the 
formation of these complexes, this would explain the inability of Ky-Del to rescue 
fiber size within the complementation studies. Further to this it would also explain why 
Ky-TM and Ky-SM were able to rescue fiber size within the complementation studies; 
with these mutations being unlikely to change protein folding drastically, and are 
unlikely to affect potential protein-protein interactions. If this is to be believed, it 
would suggest that the TGN/PROT domain and the catalytic residues have been 
conserved to maintain the precise 3D structure. This would in turn imply that small 
sequence variances seen within other species, should not impact function, as protein 
interactions will depend on the secondary and tertiary structure of the TGN/PROT 
domain. Therefore, large complexes can still form, like the IGFN1-FLNC-KY 
complex, facilitating Z-disk stabilisation, despite the mutations and small sequence 
differences seen between species. 
One hallmark commonly seen within Ky deficiencies in both mice and humans is a 
large FLNC aggregates. It was suggested by Jokl, et.al., (2018) that these FLNC 
aggregates occurred due to dysregulation of the CASA pathway, which has been 
suggested to clear damaged FLNC.  It could also be plausible that KY could aid the 
localisation of FLNC to the Z-disk, occurring through complex formation with IGFN1 
and FLNC (Baker, et.al., 2010). Therefore, if KY is unable to bind FLNC this could 
lead to the FLNC aggregation observed within ky/ky mice and humans. Furthermore, 
within FLNC myopathies, which result in myofibrillar disintegration (a hallmark 
observed within ky/ky mice and KY myopathies; it was suggested that the sequestering 
of FLNC into large aggregates, and therefore away from Z-disks, preferentially caused 
the phenotype (Ruparelia et.al., 2016). The authors showed that overexpression of the 
mutant FLNC (FLNCW2710X) which typically forms these large aggregates could 
correctly localise to the Z-disk, and rescue the fiber disintegration phenotype within a 
zebrafish model of a FLNC knockdown. Interestingly these researchers also showed 
that BAG3 was contained within FLNCW2710X aggregates, which is the same finding 
identified within the ky/ky soleus fibres (Jokl, et.al., 2018). Hence, if FLNC is not able 
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to properly localise within Ky myopathies, this may contribute to the severe phenotype 
seen within these cases.  
6.4 KY’s Z-disk Localisation 
KY’s only distinguishable feature is the highly conserved TGN/PROT domain. Hence 
it was hypothesised that this domain was causing Z-disk localisation. Here we have 
shown this not to be the case, which has indicated that the region causing Z-disk 
localisation is held elsewhere within the protein. Looking at the amount of evolution 
along the KY protein (Figure 20.C), the C-terminus appears to have evolved the least. 
Thus, the domain controlling Z-disk localisation may be contained within the C-
terminus, due to the fact there is a higher level of conservation compared to the rest of 
the protein. 
6.5 The human KY gene 
It was always likely the hKY would localise to the Z-disk, as the main body of the 
protein (not including the extra region in which the NLS is held), is highly similar to 
the mouse KY. It is probable that this region is mechanistically acting in a similar 
fashion to the mKY, with the TGN/PROT domain performing a similar, if not the same 
role. Again, correlating with the fact that similar pathways would be disrupted within 
the human KY myopathies and the ky/ky mouse, and thus producing the similar 
phenotype seen. The striking similarities seen between the muscular pathology of ky/ky 
mice and humans, reiterates a relationship between gene similarity and function. 
Specifically, the development of extremely small myofibers with internalised nuclei, 
alongside large FLNC and Xin aggregates. Although there are some subtle differences 
between these phenotypes. The mouse phenotype in most cases is more severe, ky/ky 
mice seem to develop scoliosis extremely quickly post weaning, and within the worst 
cases showing whole body tremors. Unlike the human KY myopathies, where mild 
muscular weakness and muscular atrophy is present, seeming to primarily affect lower 
limbs, and cause a milder scoliosis which in general developed much later within the 
disease (Yogev, et.al., 2017; Hedberg-Oldfors, et.al., 2016). 
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These subtle differences in the myopathies may be attributed to the NLS found within 
the primate KY. In each of the human KY myopathies, the nonsense mutation occurred 
within the main body of the KY protein, not affecting the NLS which is located at the 
N-terminus. These nonsense mutations are unlikely to affect the expression of KY. 
Both the 7-year-old girl with a nonsense mutation within KY (Hedberg-Oldfors, et.al., 
2016) and the 12 Bedouin individuals who had nonsense mutations within exon 1 
(Yogev, et.al., 2017), showed high levels of KY mRNA transcripts within muscular 
organs. Straussberg, et.al., (2016) reported that non-sense mediated decay may be 
occurring but could not confirm this due to unsuccessful antibodies used within 
western blots. Finally, no western blots or rt-PCR were performed on the last reported 
KY myopathy within the Iranian patient who held a nonsense mutation within exon 4 
(Ebrahimzadeh, et.al., 2018). This data suggests these KY variants are not being 
degraded through nonsense mediated decay. If these transcripts are not being degraded 
it would inevitably result in the production of truncated proteins and would therefore 
leave the region encoding the NLS. Therefore, this may allow the truncated proteins 
to localise to the nucleus and perform part of KY’s role within primates, and this may 
explain the minor pathological differences observed between ky/ky mice and humans 
KY myopathies. 
6.6 The Nuclear localisation signal conserved within primates 
In order for muscular hypertrophy to occur there must be an upregulation of synthetic 
pathways allowing for protein synthesis (Chen, et.al. 2016). Therefore, the hKY could 
be acting in a similar fashion to other well-defined nucleocytoplasmic proteins. The 
previously mentioned proteins Ankrd2, and Csrp3 are examples of nucleocytoplasmic 
shuttles, both of which have been implicated as stretch receptors (Cenni, et.al., 2019; 
Boateng, et.al., 2009). Both of these proteins localise to the nucleus through the use of 
a NLS in response to different stressors. Ankrd2 responds to mechanical stimulation 
and reactive oxygen species (ROS) (Cenni, et.al., 2019). Furthermore Ankrd2, Csrp3, 
and FLNC were all shown to be upregulated in hypertrophy and regrowth conditions 
(Chaillou, et.al., 2015). 
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Another well-defined muscular nucleocytoplasmic protein is the muscle glycogen 
synthase (MGS), which is known to accumulate and aggregate within the nucleus in 
times of glucose deprivation. MSG like the hKY also contains NLS which causes a 
“speckled” nuclear localisation pattern, highly reminiscent of hKY and IGFN1_V1. 
MSG accumulates and aggregates within nuclear compartments giving the “speckled” 
appearance. Furthermore, they showed its nuclear localisation was not determined by 
the enzymatic sites, but through an independent region on the protein. In conclusion 
the authors suggested that MSG may act as a sensor of cellular energy reserves (Cid, 
et.al., 2005). These cases highlight that a NLS can be utilised in order to respond to 
stressors independently of its primary function, providing good evidence that the hKY 
could be acting as a stress response protein, in this case the stress being stretch. It's 
plausible to believe that h could be detecting mechanical stress at the Z-disk, a known 
anchor for nucleocytoplasmic proteins and a site for intracellular signalling (Luther, 
2009). Then, in response to mechanical stress, translocate to the nucleus and initiate a 
transcriptional response.  
It is highly intriguing that only primates have evolved to maintain a NLS within their 
KY protein. There are many significant differences between primates and other 
placental mammals. The number and complexity of muscles that primates hold differ 
to other species. Also, primates are one of few species that are able to move regularly 
within three dimensions. All non-human primates rely on the ability to climb, living, 
sleeping, and evading predators within the trees. It has been theorised that early in the 
primate evolution their morphological features and locomotor patterns evolved due to 
climbing (Hanna and Schmitt, 2011), making primate locomotion very unique. The 
most distinct locomotion difference being that primates hold a different walking gait 
pattern (Larson, 1998), where a diagonal-sequence diagonal couplet gait is used. These 
specific gait characteristics are thought to have evolved due to specific mechanical 
challenges linked to climbing and the movement on vertical supports (Hanna, et.al., 
2017). Furthermore, a study comparing the total energy expenditure from a range of 
primates and other placental mammals, has shown that on average, primates expend 
half the predicted amount (Pontezer et.al., 2014). The authors suggested this 
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represented a “systemic metabolic adaptation for low energy expenditures'' which was 
not explained by differences in physical activity.  
Overall, the evidence presented shows primates have evolved to be able to perform a 
wide range of physical activities, highly different to other mammals. These significant 
differences may represent the reason as to why primates have evolved to conserve a 
NLS within KY, potentially answering the reason behind the significant energy 
expenditure differences between primates and other placental mammals.  
6.7 IGFN1 and KY’s Interaction 
KY’s interaction with IGFN1 still remains elusive. The fact that Ky deficient muscles 
show muscle atrophy and an inability to grow through muscle hypertrophy, could 
suggest that KY is able to modulate IGFN1’s ability to promote muscular atrophy. 
More recent data has shown IGFN1 interacts with the proteasomal subunits (Psmd2, 
11 and 12) (Cracknell, et.al., 2020), it has been suggested that IGFN1 may be acting 
as a scaffold for proteasomal subunits at the Z-disk. Non primate KY does not localise 
to the nucleus, suggesting non primate KY’s interaction with IGFN1 would solely 
occur within the myoplasm. Potentially IGFN1 could be directed to misfolded proteins 
at the Z-disk via KY, then utilise interactions with proteasomal subunits to aid their 
clearance. Thus, if this is true it may explain the wider Z-disk observed within the 
ky/ky pathology, as misfolded proteins may be contained within the Z-disk. Therefore, 
this could suggest that the IGFN1-FLNC-KY complex may not only be required as a 
protein scaffold but may also allow for the detection and clearance of misfolded 
proteins within the Z-disk. Conversely, KY could be protecting proteins from 
premature degradation, through the formation of complexes. 
IGFN1 expression positively correlates with atrophic signalling (Rahimov, et.al., 
2011), and has been suggested to down regulate protein synthesis via an inhibitory 
interaction with eEF1A occurring within the myoplasm (Mansilla, et.al., 2008).  
Cumulatively, this data provides evidence that IGFN1 may be involved within the 
inhibition of protein synthesis in atrophic conditions. Therefore, if IGFN1 is inhibiting 
the induction of proteins synthesis via eEF1A and this pathway is overstimulated this 
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could prevent muscle fibers from being able to grow via hypertrophy, as new proteins 
would need to be produced for this to occur. Therefore, if KY is able to bind IGFN1 
and prevent the interaction with eEF1A, this could explain the atrophy seen within 
ky/ky muscles. As IGFN1 is not inhibited by KY, this would therefore lead to a constant 
inhibition placed upon eEF1A. 
Intriguingly the mKY has never been seen within the nucleus, always localising to the 
cytoplasm.  Here it was shown that the hKY can localise to the nucleus where it is able 
to form clusters with IGFN1_V1 and hKY (Figure 24). Therefore, it was asked if 
overexpression of IGFN1_V1 could cause the mKY to localise to the nucleus. Results 
indicated no co-localisation of these two proteins (Figure 25) and reiterating the mKY 
to be a cytoplasmic protein. This data shows that IGFN1 does not induce the nuclear 
localisation of KY. This distinct lack of colocalization between IGFN1_V1 and mKY 
was extremely interesting, as they are known interacting partners. Curiously, previous 
attempts to Immunoprecipitated individual complexes of IGFN1_V1 and KY from 
mouse skeletal muscle extracts were not successful. Although affinity purified KY was 
able to form complexes with IGFN1_V1 and FLNC from C2C12 myoblast extracts 
(Baker, et.al., 2010). Furthermore, in this case the authors then suggested that IGFN1, 
FLNC, and KY form a complex which provides support to the Z-disk. This may 
explain why an interaction between the mKY and IGFN1_V1 was not seen when co-
transfected into C2C12 myoblasts, as their interaction may be exclusive to the Z-disk 
within a fully differentiated myotube. 
6.8 Ky as a regulator of protein turnover 
The ky/ky mouse and human KY myopathies are known to have a prominent pathology. 
The build-up of large sarcomeric protein aggregates (such as FLNC) is one of these 
hallmarks, commonly seen within myofibrillar myopathies. Previous work has shown 
an upregulation of the co-chaperone BAG3 in Ky deficient models (Jokl, et.al., 2018). 
The cochaperone BAG3 is part of the CASA system and allows for the formation of 
the CASA complex. BAG3 has been reported to be essential for muscle maintenance 
(Arndt, et.al., 2010) and allows for mechanotransduction (Ulbricht, et.al., 2013). 
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Furthermore, BAG3 has been suggested to increase the transcription of FLNC through 
interactions with components of the Hippo system (Ulbricht, et.al., 2013). It has been 
reported in ky/ky mice that a transcriptional upregulation of BAG3 was observed, and 
within the pathological soleus, there was evidence of impaired BAG3 turnover (Jokl, 
et.al., 2018).  
6.9 Future Work 
6.9.1 In-Silico Analysis 
Evolutionary analysis on the NLS conserved within primates 
Extensive phylogenetic analysis should be undertaken to further understand the 
evolutionary history of Ky. The current research indicates that many species have 
removed the NLS conserved within primates. Identification of the time point at which 
this occurred could better aid our understanding as to why this happened, and why 
primates have specifically conserved this region.  Furthermore, identification of the 
key motifs conserved among species may help to understand the function of each 
conserved region, identifying a potential region which allows for Z-disk localisation. 
Using the MEME program (Bailey and Elkan, 1994), predictions of potential patterns 
within the full amino acid sequence can be acquired. Thus, these can be used to identify 
key regions which may have a critical role within KY’s function. Overall extensive in-
silico analysis could better aid our understanding of this complex protein, furthering 
our knowledge of conserved regions. To date only one highly conserved region has 
been identified this being the TGN/PROT domain. 
6.9.2 In-vitro Experiments  
Conformation that KY’s TGN/PROT domain can aid protein interactions 
Here it has been assumed that the TGN/PROT domain mediates protein-protein 
interactions. In order to confirm this, we could map the interacting domains in the KY 
protein for IGFN1 using a yeast two hybrid.  
Validation that the hKY is acting as a stress response protein 
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Therefore, in order to validate that the hKY is responding to mechanical tension, 
C2C12 myoblasts which have been transfected with hKy-eGFP, should be exposed to 
osmotic shock through the use of Sorbitol, which has been previously used to induce 
osmotic shock (Wang, et.al., 1999). Thus, if the hKY is translocating to the nucleus to 
under mechanical tension, we should observe a higher proportion of hKY localised 
within the nucleus within conditions of osmotic shock. This would allow us to validate 
that this NLS is being used to respond to mechanical stress.  
6.9.3 In-vivo Experiments 
Identification of the region within KY allowing for Z-disk localisation 
As suggested above the minimal domain required for Z-disk localisation could be 
present within the C-terminus. Therefore, in order to identify this minimal domain, we 
can electroporate a series of KY constructs containing a series of deletions across the 
C-terminus. Then assess the ability fo these constructs to correctly localise to the Z-
disk. 
Conformation of nuclear interaction between IGFN1_V1 and hKY in-vivo 
Here it has been shown that the hKY is able to form nuclear clusters with IGFN1_V1 
when co-transfected within C2C12 myoblasts, likely representing a nuclear protein 
interaction between these two proteins. In order to confirm this is not exclusive to 
myoblasts and can occur in fully differentiated myotubes, both constructs need to be 
electroporated into the TA of mice. Although, it is likely only a few fibers will contain 
both constructs, these should have a significant enough expression for valid 
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Placing reflex.  
The placing reflex was commonly used to allow for the phenotyping of Ky/Ky mice. 
As Ky/Ky mice are known to have weak postural muscles, there are unable to reach 
out and grab a ledge in front of them. 
 
 
In-silico Analysis of the NLS within hKy-X5. 
Two NLS signal predicting software’s were used to identify the NLS with hKy X5. 
Firstly, NLStradamus was used and gave us the readout below (Figure 2). The software 
showed us the motif most likely to cause nuclear localisation. This software is 
available at http://www.moseslab.csb.utoronto.ca/NLStradamus/  
 
Figure 1. Placing reflex. Image taken from (Blanco, et.al., 2001). The BDL (Wildtype) 
strain of mice show a normal placing reflex, where mice will reach out towards a ledge. 
The Ky/Ky mouse shows an inability to reach towards the ledge due to weak paraspinal 






Figure 2. NLS software results. A cut of score of 0.9 was applied, as seen on the graphic. 





Muscle sections from Ky/Ky patients 
Patients with loss of function Ky mutations have an extremely prevalent phenotype. 
The muscular pathology presenting with heterogenous fiber sizes, including extremely 













Figure 3. Heterogenous fibers and internalised myonuclei within Ky loss of function 
patients. Both patients present with extremely small myofibers alongside internalised 
nuclei. A) Image taken from Herdberg-Oldfors, et.al., 2016. Available at: 
https://www.nature.com/articles/ejhg201698. B) Image taken from Yogev, et.al., 2017. 
Available at: https://www.nature.com/articles/ejhg201785  
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